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A B S T R A C T
Background
Asthma exacerbations in school-aged children peak in autumn, shortly after children return to school following the summer holiday.
This might reflect a combination of risk factors, including poor treatment adherence, increased allergen and viral exposure, and altered
immune tolerance. Since this peak is predictable, interventions targeting modifiable risk factors might reduce exacerbation-associated
morbidity and strain upon health resources. The peak occurs in September in theNorthernHemisphere and in February in the Southern
Hemisphere.
Objectives
To assess the effects of pharmacotherapy and behavioural interventions enacted in anticipation of school return during autumn that
are designed to reduce asthma exacerbations in children during this period.
Search methods
We searched the Cochrane Airways Group Trials Register, ClinicalTrials.gov, the World Health Organization International Clinical
Trials Registry Platform, reference lists of primary studies and existing reviews, and manufacturers’ trial registries (Merck, Novartis and
Ono Parmaceuticals). We searched databases from their inception to 1 December 2017, and imposed no restriction on language of
publication.
Selection criteria
We included all randomised controlled trials comparing interventions aimed specifically at reducing autumn exacerbations with usual
care, (no systematic change in management in preparation for school return). We included studies providing data on children aged 18
years or younger.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Two review authors independently screened records identified
by the search and then extracted data and assessed bias for trials meeting the inclusion criteria. A third review author checked for
accuracy and mediated consensus on disagreements. The primary outcome was proportion of children experiencing one or more asthma
exacerbations requiring hospitalisation or oral corticosteroids during the autumn period.
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Main results
Our searches returned 546 trials, of which five met our inclusion criteria. These studies randomised 14,252 children to receive either
an intervention or usual care. All studies were conducted in the Northern Hemisphere. Three interventions used a leukotriene receptor
antagonist, one used omalizumab or a boost of inhaled corticosteroids, and the largest study, (12,179 children), used a medication
reminder letter. Whilst the risk of bias within individual studies was generally low, we downgraded the evidence quality due to
imprecision associated with low participant numbers, poor consistency between studies, and indirect outcome ascertainment.
A US study of 513 children with mild/severe asthma and allergic sensitisation was the only study to provide data for our primary
outcome. In this study, the proportion of participants experiencing an exacerbation requiring oral corticosteroids or hospital admission
in the 90 days after school return was significantly reduced to 11.3% in those receiving omalizumab compared to 21.0% in those
receiving placebo (odds ratio 0.48, 95% confidence interval 0.25 to 0.92, moderate-quality evidence). The remaining studies used
alternative exacerbation definitions. When data from two leukotriene receptor antagonist studies with comparable outcomes were
combined in a random-effects model, there was no evidence of an effect upon exacerbations. There was no evidence that a seasonal
medication reminder letter decreased unscheduled contacts for a respiratory diagnosis between September and December.
Four studies recorded adverse events. There was no evidence that the proportion of participants experiencing at least one adverse event
differed between intervention and usual care groups. Lack of data prevented planned subgroup and sensitivity analyses.
Authors’ conclusions
Seasonal omalizumab treatment from four to six weeks before school return might reduce autumn asthma exacerbations. We found
no evidence that this strategy is associated with increased adverse effects other than injection site pain, but it is costly. There were no
data upon which to judge the effect of this or other seasonal interventions on asthma control, quality of life, or asthma-related death.
In future studies definitions of exacerbations should be provided, and standardised where possible. To investigate possible differential
effects according to subgroup, participants in future trials should be well characterised with respect to baseline asthma severity and
exacerbation history in addition to age and gender.
P L A I N L A N G U A G E S U M M A R Y
Interventions to prevent asthma attacks in children upon return to school in the autumn
Background
Asthma is a long-term condition affecting the lungs. It is themost common long-term condition affecting children.One in 11 children in
the United Kingdom have asthma. People with asthma can experience asthma ’attacks’ of coughing, wheezing, and difficulty breathing.
Each year there is a peak in asthma attacks after school restarts in autumn. The likely reason for this is that children are exposed to
more viruses that can trigger asthma. Children may also have taken their regular medication less consistently with the break in routine
over the summer.
As this increase in attacks at the start of the school year is predictable, and the reason for it is somewhat understood, it might be
preventable. Approaches to reducing autumn asthma attacks include using extra medications when school restarts or medication
reminders during the school holiday.
Main findings
Our searches found 546 trials, of which five were relevant. In total, 14,252 children were randomly assigned to receive either an
intervention targeting autumn asthma attacks or usual care. Four small studies (approximately 200 to 1200 children in each) gave
children extra asthma medication; these additional medications were omalizumab, leukotriene receptor antagonist tablets, or increased
doses of inhaled steroids. One study sent a medication reminder letter over the summer holidays to parents of children with asthma.
One trial gave children either omalizumab or placebo. Omalizumab is an antibody designed to alter the immune response. It was given
by injection regularly over four to six weeks before school return (i.e. over the bulk of the summer holidays). The children in this
study had known allergic asthma. The study showed that omalizumab might reduce autumn attacks. Eleven per cent of those receiving
omalizumab had an asthma attack during the first 90 days compared to 21% of those receiving placebo.
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Three studies used leukotriene receptor antagonist tablets, either montelukast or pranlukast. Although the results of one study suggested
that seasonal montelukast might reduce autumn attacks, there was no evidence of reduced attacks in the other two later trials, including
a second larger trial of montelukast.
There was no evidence that sending a reminder letter reduces the number of children requiring an unplanned healthcare contact.
No study provided evidence that the total number of children experiencing adverse events was greater in the intervention than in the
usual care group.
Limitations
Ourfindingswere limited by the small numbers of studies identified and because these studies used different interventions and definitions
of asthma exacerbations. Further research is needed to better understand how to prevent seasonal attacks, including interventions
suitable for children with mild asthma, where expensive and painful treatments are not justified.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Omalizumab compared to usual care for autumn asthma exacerbations in children
Patient or population: autumn asthma exacerbat ions in children
Setting: community
Intervention: omalizumab
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with omalizumab
Exacerbat ions
assessed with: hospi-
tal admissions or oral
steroid requirement in
those with stage 2-5
asthma
follow-up: 90 days
210 per 1000 113 per 1000
(62 to 197)
OR 0.48 (0.25 to 0.92) 348
(1 RCT)
⊕⊕⊕©
MODERATE 1
Absolute ef fects calcu-
lated using control risk
of 21.0% f rom Teach
2015a.
Exacerbat ions
assessed with: hospital
admissions or OCS re-
quirement in those with
stage 5 asthma
follow-up: 90 days
326 per 1000 152 per 1000
(76 to 281)
OR 0.37
(0.17 to 0.81)
184
(1 RCT)
⊕⊕⊕©
MODERATE 1
Absolute ef fects calcu-
lated using control risk
of 32.6% f rom Teach
2015a.
Exacerbat ions
assessed with: hospital
admissions or OCS re-
quirement in those with
stage 2-4 asthma
follow-up: 90 days
127 per 1000 83 per 1000
(31 to 207)
OR 0.63
(0.22 to 1.79)
164
(1 RCT)
⊕⊕⊕©
MODERATE 1
Absolute ef fects calcu-
lated using control risk
of 12.7% f rom Teach
2015a.
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Adverse events
assessed with: number
of children experienc-
ing 1 or more adverse
events asthma stage 2-
5
follow-up: 17 to 19
weeks
548 per 1000 546 per 1000
(425 to 657)
OR 0.99
(0.61 to 1.58)
361
(1 RCT)
⊕⊕⊕©
MODERATE 1
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OCS: oral cort icosteroid; OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded once for imprecision because few children studied.
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B A C K G R O U N D
Description of the condition
Asthma is a chronic disease of the airways characterised by recur-
rent episodes ofwheezing, breathlessness, and cough, togetherwith
variable expiratory airflow limitation. Symptoms are frequently
associated with airway inflammation and bronchial hyper-respon-
siveness (GINA 2017). Asthma can affect people of all ages, al-
though childhood onset is common. Asthma is diagnosed clini-
cally based upon evaluation of symptoms and response to phar-
macotherapy. There is no specific diagnostic test, although spiro-
metric measurement of reversible airflow limitation and indirect
or direct tests of airway hyper-responsiveness can be useful (GINA
2017).
The number of people with asthma globally is currently estimated
to be approximately 300 million, and is expected to grow to closer
to 400 million by 2025 (WHO 2007). Asthma is the most com-
mon chronic disease among children (Asher 2014). The Interna-
tional Study of Asthma and Allergies in Childhood (ISAAC), con-
ducted between 2002 and 2003, found the highest prevalence of
childhood wheeze in Latin and North America, and in English-
speaking countries in Australasia and Europe (Asher 2006). More
than 1 million children (1 in 11) in the United Kingdom are cur-
rently believed to be living with asthma (Asthma UK 2016).
Symptom exacerbations can be triggered by a number of environ-
mental challenges, including pollutants (Lierl 2003; Schildcrout
2006), physical activity (Randolph 2013), and respiratory in-
fections or allergens (Brandt 2015; Ito 2015; Murray 2006;
Olenec 2010). People whose airway inflammation is not ade-
quately controlled are more vulnerable to exacerbations than those
on adequate therapy with good treatment adherence. Poorly con-
trolled day-to-day asthma symptoms can limit activities, includ-
ing schooling, and impair sleep quality and overall quality of life
(Kiotseridis 2013; Teyhan 2015; van Maanen 2013). However, it
is asthma exacerbations or ’attacks’ - acute or subacute progressive
worsening of symptoms - which pose the greatest danger to people
with asthma (NAEPP 2007). Asthma exacerbations are also asso-
ciated with reduced school or work attendance and are the most
important contributor to the economic and social costs of asthma
(Bahadori 2009; Hoskins 2000; Ismaila 2013).
A seasonal peak in exacerbation rates has been consistently demon-
strated in the autumn months (September to November) across
multiple Northern Hemisphere countries (Fleming 2000; Gergen
2002).More specifically, exacerbation rates peak in September fol-
lowing the summer school holiday and in line with the start of the
autumn term (Johnston 2006). Equivalent peaks during February
have been reported in Southern Hemisphere countries (Lincoln
2006; Lister 2001). The autumn peak in asthma exacerbations is
temporally linked to children returning to school and most pro-
nounced in school-aged children (Corne 2002). Hospitalisations
and emergency department visits attributable to asthma demon-
strate an initial peak in school-aged children; however, this is fol-
lowed within days by increased hospitalisations in preschool chil-
dren and a more blunted peak in adults up to the age of 50 years
(Sears 2008). There is evidence that viral infections, particularly
rhinovirus, may contribute to this seasonality (Johnston 1996;
Johnston 2005; Thumerelle 2003), but suboptimal asthma treat-
ment and changes in tolerance may also be contributing factors
(Johnston 2005; Tovey 2011). Not only do viral infections trigger
asthma exacerbations, but there is also evidence that asthmatic in-
dividuals are more susceptible to rhinovirus infection than those
without asthma (Baraldo 2012; Wark 2005). Individuals at par-
ticular risk of asthma exacerbation have been identified as those
with more severe disease, greater degree of atopy, and recent exac-
erbations (Teach 2015b).
Description of the intervention
A number of interventions including asthma education pro-
grammes, action plans, self monitoring, and self initiation of oral
corticosteroid (OCS) treatment have been shown to reduce both
symptom exacerbations and need for unscheduled acute care in
children with asthma (Bhogal 2006; Guevara 2003; Vuillermin
2011). Given that the seasonality of asthma exacerbations in
school-aged children is predictable and repeatable, it is reasonable
to assume that management strategies that anticipate increased
risk in the autumn might reduce exacerbation frequency during
this period. Whilst the exact aetiology of the seasonal peak in
asthma exacerbations is not fully understood, any change in man-
agement aimed at improving asthma control in anticipation of
the autumn school return, if successful, could offer protection
against the increased risk recognised to be associated with this
event. Therapies that have been demonstrated to reduce the sea-
sonal excess of exacerbations in the autumn, in addition to the
annual number of exacerbations, include year-round treatment
with the anti-immunoglobulinE (IgE)monoclonal antibody oma-
lizumab (Busse 2011); or with high-dose inhaled corticosteroids
(ICS) (Szefler 2008). However, omalizumab is an expensive and
sometimes painful treatment, whilst high-dose ICS are associated
with adverse effects upon growth and bone health (Pruteanu 2014;
Wong 2000).
Given the pragmatic difficulties associatedwithminimising viral or
allergen exposure, two main potential strategies remain that might
reduce autumn asthma exacerbations whilst minimising treatment
costs and adverse effects. The first strategy would be to add on, or
increase, asthma pharmacotherapy before the autumn period; the
second strategy would be to focus upon treatment adherence and
achieving symptom control before and during the autumn. It is
anticipated that school-aged children would gain the greatest ben-
efit from an intervention targeting seasonal exacerbations, since
the autumn peak in exacerbations is most pronounced in this age
group. Similarly, greater benefit might be demonstrable in those
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at increased risk of exacerbation due to poor treatment adherence,
severe disease, allergic phenotype, or recent exacerbation.
Add-on therapies include those aimed at reducing airway inflam-
mation, such as corticosteroid preparations, macrolide antibiotics,
or leukotriene receptor antagonists (LTRAs). Alternatively, agents
such as biologics which more specifically target the interaction be-
tween the immune response, allergens, and viral infection might
be selected (Beck 2004; Durrani 2012; Gill 2010). Important con-
siderations with respect to choice of intervention include onset of
action and ease of administration, in addition to cost and adverse
effect profile.
Strategies to improve treatment adherence require adherence sta-
tus to be assessed, and barriers leading to non-adherence to be
identified and addressed. The success of adherence interventions
can be increased by a number of strategies, including the provi-
sion of biofeedback, Feldman 2012, and increasing motivation via
motivational interviewing techniques (Borrelli 2007). Neverthe-
less, it is difficult to achieve sustained adherence (Jonasson 2000).
Targeting adherence interventions to periods of increased exacer-
bation risk might increase their overall benefit.
How the intervention might work
Upon return to school in the autumn children are exposed to al-
lergens and respiratory infections by close contact with their class-
mates (Cai 2011; Krop 2014). During the autumnmonths mould
spores, which can act as a trigger for allergic asthma, are more
abundant than at other times of the year (de Ana 2006). How-
ever, the sequential periods of peak risk demonstrated by school-
aged children, younger children, and adults suggest a transmissible
agent is responsible. In support of this are findings from virological
studies that demonstrate increased viral isolations during autumn,
notably rhinovirus, from children with asthma compared to those
without, with the highest rates of isolation measured in those ad-
mitted to hospital with an asthma exacerbation (Johnston 2005;
Thumerelle 2003).
Changes in routine during the summer holidays and lower per-
ceived risk of cold weather or respiratory infection might be as-
sociated with both intentional reduction in preventer medication
and unintentional poor adherence (Johnston 2005; Sears 2008). A
higher rate of exacerbation has been reported in people prescribed
bronchodilator therapy alone than in those prescribed an inhaled
steroid or other preventer medication (Johnston 2005; Murray
2006). Furthermore, within a trial of seasonal omalizumab treat-
ment, school-aged children with mild asthma but poor control,
as evidenced by an exacerbation during the run-in period of four
to nine months, experienced a significant reduction in exacerba-
tion frequency (Teach 2015a). Exacerbation frequency could not
be significantly reduced in those with mild asthma but without
a recent admission (Teach 2015a). Any intervention based upon
reinforcing or increasing adherence to regular treatment, moni-
toring symptoms to assess control, or a seasonal enhancement of
treatment might potentially reduce ongoing airway inflammation
and the likelihood of viral infection triggering an exacerbation.
Why it is important to do this review
Although the asthma epidemic observed in the 1980s and 1990s
appears to have stabilised, a study from the NorthernHemisphere
demonstrates that emergency care contacts due to asthma remain
significantly higher in September than in other months (Larsen
2016). Despite this, current national and international guidelines
offer no guidance on strategies to reduce seasonal exacerbations
after autumn school return. Following the recent successful trial
of seasonal omalizumab, which demonstrated reduced exacerba-
tions amongst children with severe or poorly controlled asthma
(Teach 2015a), it is important to identify whether a similar ef-
fect can be achieved with less invasive and less expensive medica-
tions. This is particularly the case in countries such as the United
Kingdom where omalizumab can only be prescribed to children
meeting strict severity criteria. A quarter of annual hospitalisa-
tions for asthma are estimated to occur in September (Johnston
2001), and acute exacerbations are the principal driver of the eco-
nomic and social costs of asthma (Bahadori 2009; Hoskins 2000;
Ismaila 2013). Interventions based upon an anticipatory change
in asthma management, if successful, could therefore substantially
reduce both the overall exacerbation rate and the strain placed
upon health services during autumn.
O B J E C T I V E S
To assess the effects of pharmacotherapy and behavioural inter-
ventions enacted in anticipation of school return during autumn
that are designed to reduce asthma exacerbations in children dur-
ing this period.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We restricted inclusion to randomised controlled trials with a con-
trol arm of usual care since currently there is no recommended
management strategy for autumn exacerbations. Studies reported
as full text, those published as abstract only, and unpublished data
were all eligible for inclusion.
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Types of participants
We included studies presenting data relating to children with
asthma. Studies needed to recruit children aged 18 years or
younger, including preschool-age as well as school-aged children.
Types of interventions
We included studies comparing interventions aimed specifically
at reducing autumn exacerbations with usual care where there is
no systematic change in management in preparation for school
return. Eligible interventions included pharmacotherapy trials and
behavioural or educational-based initiatives.
Types of outcome measures
Primary outcomes
The primary outcome was number of children (adjusted for the
number of participants per group) experiencing one or more
asthma exacerbations during the autumn period (the first three-
month period following the autumn school return) or during the
intervention period if this included the autumn months. An ex-
acerbation was defined as increased asthma symptoms requiring
treatment with OCS or hospitalisation.
Secondary outcomes
1. Number of children experiencing exacerbations of asthma
requiring hospitalisation.
2. Number of children experiencing exacerbations of asthma
requiring paediatric intensive care unit admission.
3. Number of asthma-related deaths.
4. Asthma control, measured by standardised tool (e.g.
Childhood Asthma Control Test (cACT) or Asthma Control
Test (ACT)).
5. Asthma-related quality of life measured by standardised tool
(e.g. Paediatric Asthma Quality of Life Questionnaire (PAQLQ)
or Asthma Quality of Life Questionnaire (AQLQ)).
6. Days of schooling (or employment, for those beyond school
age) missed.
7. Adverse events (including serious adverse events).
For each outcome data were collected throughout the autumn
period or the intervention period (as for the primary outcome) in
both the intervention group and the usual therapy group.
We did not require report of the primary outcome as an inclusion
criterion for the review.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group’s Trials
Register, which is maintained by the Information Specialist for
the Group. The Register contains trial reports identified through
systematic searches of several sources:
• monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
• weekly searches of MEDLINE Ovid SP 1946 to date;
• weekly searches of Embase Ovid SP 1974 to date;
• monthly searches of PsycINFO Ovid SP 1967 to date;
• monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date;
• monthly searches of AMED EBSCO (Allied and
Complementary Medicine) all years to date;
• handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, can be found in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review.
We also conducted a search of ClinicalTrials.gov
(www.clinicaltrials.gov) and the World Health Organization In-
ternational Clinical Trials Registry Platform (www.who.int/ictrp/
en/). We searched all databases from their inception to 1 Decem-
ber 2017, and imposed no restriction on language of publication.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references.We searched relevant manufacturers’
websites for trial information (Merck, Novartis and Ono Pharma-
ceuticals).
On 1 December 2017 we searched for errata or retractions
from included studies published in full text on PubMed (
www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (KCP, MA) independently screened for po-
tential inclusion titles and abstracts of all the studies identified
as a result of the search and coded them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. We retrieved the
full-text study reports/publications, and two review authors (KCP,
MA) independently screened the full texts and identified studies
for inclusion and recorded reasons for exclusion of the ineligible
studies. Any disagreements were resolved through discussion or,
if required, by consultation with a third review author (DK). We
identified and excluded duplicates and collatedmultiple reports of
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the same study so that each study, rather than each report, was the
unit of interest in the review. We recorded the selection process us-
ing EPPI-Reviewer 4 and completed a PRISMA flow diagram and
Characteristics of included studies table (EPPI-Reviewer 4 2010;
Moher 2009).
Data extraction and management
We used a data collection form for study characteristics and out-
come data that was piloted on two studies in the review. Three
review authors (KCP, KMH, MA) extracted study characteristics
from included studies in triplicate. We extracted the following
study characteristics.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention type, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (KCP, MA) independently extracted outcome
data from the included studies. We noted in the Characteristics
of included studies table if outcome data were not reported in
a usable way. Any disagreements were resolved by consensus or
by involving a third review author (KMH) when necessary. One
review author (KCP) transferred data into the Review Manager 5
file (RevMan 2014). We double-checked that data were entered
correctly by comparing the data presented in the systematic review
with the data in the study reports. A second review author (DK)
spot-checked study characteristics for accuracy against the trial
report.
Assessment of risk of bias in included studies
Two review authors (KCP, MA) independently assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements were resolved by discussion or by involving
another review author (KMH) when necessary. We assessed the
risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ tables included within the
Characteristics of included studies table.We summarised the ’Risk
of bias’ judgements across different studies for each of the domains
listed. We considered blinding separately for different key out-
comes where necessary (e.g. for unblinded outcome assessment,
risk of bias for asthma-relatedmortality may be very different than
for a patient-reported asthma control scale). Where information
on risk of bias related to unpublished data or correspondence with
a trialist, we noted this in the Characteristics of included studies
table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
(Pike 2016) and reported deviations from it in the Differences
between protocol and review section.
Measures of treatment effect
We analysed dichotomous data as odds ratios.
We undertookmeta-analyses only where this wasmeaningful, such
as when the interventions, participants, outcomes, and underlying
clinical question were similar enough for pooling to make sense.
Unit of analysis issues
We considered asthma exacerbation a dichotomous outcome us-
ing participants as the unit of analysis. The odds of exacerbation
in the intervention group during the intervention were compared
to the odds of exacerbation in individuals receiving usual therapy.
Wheremultiple changes in management strategy were included in
the original studies (e.g. seasonal omalizumab or a steroid boost
in addition to usual therapy), the odds of exacerbation in each
group that included a change in management were compared to
the group receiving usual care only or usual care with a placebo.
For large-scale behavioural interventions (e.g. those involving con-
tacting families in late summer to remind them of the need for
treatment adherence), the unit of allocation may be at the level of
primary care practice level rather than the individual. Where this
was the case, we included results only if the original trial accounted
for clustering or if it was possible to adjust for this by calculating
a design effect.
Dealing with missing data
We contacted investigators or study sponsors in order to verify
key study characteristics and to obtain missing numerical outcome
data where possible (e.g. if an odds ratio was presented without a
confidence interval).
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Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the tri-
als in each analysis. Where possible we intended to report the I²
statistic, and if we identified substantial heterogeneity (I² > 50%)
to explore possible causes by prespecified subgroup analyses.
Assessment of reporting biases
Had we been able to pool more than 10 trials, we intended to
create and examine a funnel plot to explore possible small-study
and publication biases.
Data synthesis
Weused an inverse variance model for outcomes where odds ratios
from the original studies were adjusted for covariables. We used a
Mantel-Haenszel model for outcomes where confounding covari-
ables were not identified and where absolute numbers of children
experiencing the outcome were reported or could be calculated.
We used Review Manager 5 software to calculate random-effects
models for all outcomes (RevMan 2014), as we expected variation
in effects due to differences in study populations and methods
(Mantel 1959). We performed a sensitivity analysis with a fixed-
effect model when we encountered significant heterogeneity.
’Summary of findings’ tables
We created ’Summary of findings’ tables for each intervention type
using the following outcomes: exacerbation occurrence (requiring
oral steroids or hospitalisation), exacerbation occurrence (defined
according to alternative definition), and adverse events. We used
the five GRADE considerations (study limitations, consistency of
effect, imprecision, indirectness, and publication bias) to assess
the quality of a body of evidence as it relates to the studies that
contributed data for the prespecified outcomes. We used methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), employing GRADEpro GDT software. We justi-
fied all decisions to down- or upgrade the quality of studies using
footnotes and made comments to aid the reader’s understanding
of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We recognised that intervention type and/or disease severity might
affect effect sizes, and therefore planned to carry out the following
subgroup analyses for all outcomes.
• An analysis separating studies based on pharmacological
interventions from those based on non-pharmacological
interventions.
• Analyses considering separately those with mild to moderate
disease (intermittent bronchodilator only; or low/moderate ICS
with or without a single add-on therapy) and those with severe
asthma (two or more add-on therapies; or high-dose ICS - daily
beclomethasone equivalents for children 5 to 12 years: ≥ 800
mcg; for children older than 12 years: ≥ 2000 mcg).
We planned to use identical primary and secondary outcomes in
subgroup analyses as in the main analysis.
We planned to use the formal test for subgroup interactions in
ReviewManager 5 to determine statistical significance of subgroup
analyses (RevMan 2014).
Sensitivity analysis
We planned to carry out the following sensitivity analyses.
• An analysis including only studies without missing data.
• An analysis excluding cluster-randomised trials (in case any
benefit in cluster-randomised trials arises due to the ’herd’ effect
of an intervention).
We also planned to re-run analyses and compare results after se-
quential exclusion of each study from any meta-analysis.
R E S U L T S
Description of studies
We included detailed descriptions of studies fulfilling the criteria
specified in the protocol in the Characteristics of included studies
section. Studies for which full texts were reviewed but were even-
tually excluded were collated along with reasons for exclusion in
the Characteristics of excluded studies section.
Results of the search
Electronic searches run in December 2017 identified 546 records.
We removed four duplicates and four abstracts where full texts
describing the same study were also identified. After screening full
texts and abstracts, we evaluated 31 full texts against the inclu-
sion criteria. We assessed 22 as not meeting the inclusion criteria,
leaving nine references to five studies for inclusion in the review
(Figure 1).
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Figure 1. Study flow diagram.
Included studies
Five studies (nine citations) met the inclusion criteria. All five re-
ported upon the effect of an intervention specifically designed to
reduce asthma exacerbations in predominantly school-aged chil-
dren following return to school in the autumn. Two studies were
funded by Merck (Johnston 2007; Weiss 2010), two by national
funding bodies, (Julious 2016 (funded by the National Institute
for Health Research) and Teach 2015a (funded by the National
Institute of Allergy and Infectious Diseases, the National Cen-
ter for Research Resources and the National Center for Advanc-
ing Translational Sciences, National Institutes of Health, Depart-
ment of Health and Human Services)), and one did not list a
funding source (Morita 2017). Between-study variation in partic-
ipant inclusion criteria, intervention type, and outcome definition
limited the opportunity for meta-analysis. For full details see the
Characteristics of included studies tables.
Design and duration
The five included studies randomised 14,252 children to receive
either an intervention or usual care. All studies were conducted in
the Northern Hemisphere. The largest study randomised 12,179
children in a cluster-randomised trial of a primary care-based pub-
lic health intervention (Julious 2016). Data were collected from
August 2013 until the end of September 2014 from the Clinical
Practice Research Datalink (CPRD), a computerised database of
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anonymised longitudinal medical records for primary care. The
remaining studies were randomised controlled clinical trials em-
ploying a pharmacological intervention; three were blinded and
one was an open study. Johnston 2007, Weiss 2010, and Morita
2017 studied interventions based uponLTRAadministration from
school return, whilst Teach 2015a compared administration of
the anti-IgE monoclonal omalizumab to a doubling of ICS dose
or placebo initiated four to six weeks before school return. Three
pharmacological studies recruited across multiple sites (Morita
2017; Teach 2015a; Weiss 2010), whilst in Johnston 2007 partic-
ipation was at a single site. In Johnston 2007, 194 children were
followed up for 45 days with no run-in period. In Weiss 2010,
1162 children were followed up for 10 weeks after a 2- to 12-
week screening period. The 513 children in Teach 2015a received
guideline-based treatment to gain asthma control during a 4- to
9-month run-in period and were followed up until 90 days after
school return. In Morita 2017, 204 children were enrolled and
randomised two to six weeks before entering a 60-day study pe-
riod.
Inclusion and exclusion criteria
All studies referenced age and asthma diagnosis in their inclusion
criteria. Julious 2016 included children aged 4 to 16 years with a
coded diagnosis of asthma within their primary care record and
a prescription for asthma medication within the last year. Four-
year-old children were analysed separately since, whilst they are
of school age in the United Kingdom, a diagnosis of asthma in
this age group was judged to be more controversial than in older
children. Children with neoplastic disease and those judged un-
suitable for the intervention by their general practitioner were ex-
cluded. Johnston 2007 included children aged 2 to 14 years with
doctor-diagnosed asthma. Additional inclusion criteria were use of
a reliever inhaler in the last year, school absence due to asthma in
the last year or significant activity limitation, history of asthma ex-
acerbations associated with respiratory viral infections, and ability
to communicate in English. Children with significant cardiores-
piratory comorbidity were excluded, as were those with an asthma
exacerbation during the month before study inception and those
using regular OCS or an LTRA. Weiss 2010 included children
aged 6 to 14 years with a history of chronic asthma needing asthma
medication in the six months preceding screening, at least one
asthma exacerbation in the previous year in conjunction with a
cold, and an alteration in environment differing from their typical
school or education environment throughout August/September.
Morita 2017 recruited 1- to 14-year-old children with physician-
diagnosed asthma, needing a rescue inhaler in the last year, and
with a history of asthma exacerbations associated with apparent
respiratory viral infections. Exclusion criteria were significant car-
diorespiratory comorbidity, regular OCS use, or an asthma exac-
erbation in the month before the treatment period. Teach 2015a
recruited children aged 6 to 17 years with an asthma diagnosis or
symptoms for more than a year and at least one asthma exacerba-
tion (requiring systemic corticosteroids or hospitalisation) within
the prior 19 months. Additional inclusion criteria were positive
perennial allergen skin test response, body weight and total serum
IgE levels suitable for omalizumab, school attendance the follow-
ing August or September, residence in a low-income census tract,
and insurance covering standard medications. There were no ex-
clusions for this study beyond not meeting these inclusion criteria.
Baseline characteristics of participants
All five studies recruited more male than female participants: in
each study 60% to 65% of participants were male. No study
reported smoking status or exposure to environmental tobacco
smoke. Only two studies reported baseline lung function: inWeiss
2010 mean forced expiratory volume in the first second of ex-
piration (FEV1) was 89.8% predicted in the intervention group
and 90.1% in the usual care group, and in Teach 2015a mean
FEV1 across both groups at randomisation was 90.2% predicted.
Only Teach 2015a systematically reported asthma severity: 195
randomised childrenwere classified as step 5 according to a severity
scale based on the National Heart, Lung and Blood Institute Ex-
pert Panel Report-3 (severe persistent symptoms requiring high-
dose ICS and one adjunctive therapy), and 318 met the criteria for
asthma severity steps 2 to 4 (mild-moderate persistent symptoms
requiring preventer medication but no more than medium-dose
ICS and one adjunctive therapy). Johnston 2007 reported that
90% of children were routinely receiving ICS, suggesting moder-
ate severity, whilst only 30% of participants in Weiss 2010 and
50% in Morita 2017 routinely received ICS at randomisation. It
is likely that the general practice-based population in Julious 2016
included more people with mild asthma than the studies recruit-
ing from secondary care.
Description of the intervention
The behavioural public health intervention was a letter sent to par-
ents/carers of school-aged children with asthma from the child’s
general practitioner reminding them tomaintain their child’smed-
ication and to collect a prescription if they were running low on
medication. The letter was sent out during the week commenc-
ing 29 July and highlighted that school return is a time when
asthma can worsen. The comparison group did not receive a let-
ter (Julious 2016). In the pharmacological studies the interven-
tions were added to usual care and compared with a placebo in
addition to usual care. In Johnston 2007, an age-specific dose of
montelukast was given from 1 September to 15 October, whilst
participants in Weiss 2010 received 5 mg montelukast from the
night before the first day of school for eight weeks. Children in
the intervention group in Morita 2017 received pranlukast 7 mg/
kg twice daily between 15 September and 14 November. In Teach
2015a, children were randomised 3:3:1 to a standard dose of oma-
lizumab based on serum IgE levels and weight, a doubling of their
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ICS dose, or placebo from 4 to 6 weeks before the start of the au-
tumn term, continuing for 90 days after school return. Only chil-
dren at steps 2 to 4 were entered into the ICS boost arm because
of concerns that very high-dose ICS provides limited additional
efficacy and increases the risk of side effects.
Outcomes and analysis
Julious 2016 studied a number of outcomes, but the primary out-
come was the proportion of children aged 5 to 16 years with un-
scheduled contacts during September 2013. Secondary outcomes
measured in September included number of unscheduled contacts
and proportion and total number of contacts (scheduled and un-
scheduled) and unscheduled contacts for a respiratory diagnosis.
These outcomes were alsomeasured throughout September toDe-
cember 2013, September 2013 to August 2014, and in September
2014 in an ’echo study’ to see if there was a maintained effect in
the year following the main study and in which there was no study
intervention. Between September 2013 and August 2014 time to
first contact, first unscheduled contact, and first unscheduled con-
tact for a respiratory diagnosis were also measured. The propor-
tion of children with scheduled contacts was measured in August
2013, August 2014, and between August 2013 and July 2014. The
number of participants collecting prescriptions was measured in
August for both years. Quality-adjusted life years (QALYs) gained
and NHS health costs were measured between August 2013 and
July 2014. Primary analyses were conducted on an intention-to-
treat basis.
The primary outcome in Johnston 2007 was percentage of days
during the intervention period with worsening asthma symptoms.
Data were inputted daily by parents/carers into a prospectively
completed sticker chart, and further data were collected by ques-
tionnaire two weeks after the end of the intervention period. The
secondary outcome was number of unscheduled care visits. Anal-
ysis was intention-to-treat. In Weiss 2010, the primary outcome
was percentage of days with worsening asthma symptoms, defined
as one or more of increased beta-agonist use, increased daytime
symptoms score, night wakening, increased ICS use, OCS rescue
or unanticipated visits to a doctor, emergency department, or hos-
pital for asthma. Secondary outcomeswere individual components
of the composite primary endpoint and adverse events. Data were
collected at 4, 8, and 10weeks of the study and analysed in the full-
analysis population (all children who received at least one dose of
study medication and had a valid measurement of the percentage
of days with worsening asthma during the study period, derived
from at least seven days of diary data). InMorita 2017, the primary
outcome was total asthma score during the 60 study days, calcu-
lated based on asthma symptoms, need for medication, and need
for an unscheduled physician visit or OCS. The secondary out-
comes were days with worse asthma symptoms, number of colds,
and days with fever. Data were analysed per protocol only from
those compliant with treatment and returning adequate outcome
data via a daily sticker chart. Teach 2015a conducted a modified
intention-to-treat analysis, analysing data from children who were
randomised, began study treatment, and had at least one study
contact during the 90-day outcome period. The primary outcome
was asthma exacerbation, defined as worsening of asthma control
requiring systemic corticosteroids or hospitalisation, during the
90-day period from the first day of each child’s school year. Sec-
ondary analyses considered exacerbations during the 90-day inter-
vention period according to subgroups based upon: exacerbation
during run-in, eosinophil count, total IgE, roach IgE, age, frac-
tional exhaled nitric oxide (FeNO), FEV1, body mass index, eth-
nicity and gender. Interferon alpha responses to rhinovirus were
measured in peripheral blood mononuclear cells from a subset of
children.
Excluded studies
During screening of titles and abstracts, we excluded studies us-
ing a hierarchy of screening criteria. We asked first whether the
study focused on asthma, followed by seasonal asthma exacerba-
tions, and then considered whether the majority of the partici-
pants were school-aged children, whether the paper focused on
exacerbations at the beginning of the autumn school term, and
compared an intervention to prevent these exacerbations to usual
care. We excluded most studies due to no mention of seasonal
asthma exacerbation or incorrect seasonal focus because the search
terms picked up many studies of seasonal rhinitis in conjunction
with asthma. Since a focus on asthma was the first stage in the
screening hierarchy, this was also a common reason for exclusion.
We excluded 22 records after viewing full texts, in most cases be-
cause the study did not focus on seasonal asthma exacerbations or
did not present data from children. We excluded two studies be-
cause they did not employ an intervention specifically designed to
reduce asthma exacerbations in children in autumn (Busse 2011;
Gerald 2012), and two studies because they did not compare an
intervention with usual care in which there is no systematic change
in management in anticipation of children returning to school
in the autumn (Prazma 2015; Yoshihara 2014); we prespecified
both study designs as exclusionary in our protocol. We outlined
details of reasons for exclusion of studies in the Characteristics of
excluded studies section.
Risk of bias in included studies
Details of our ’Risk of bias’ assessment for each included study
and the reasoning behind our ratings can be found in the
Characteristics of included studies section; a summary of ’Risk
of bias’ judgements by study and domain (selection bias, perfor-
mance bias, detection bias, attrition bias, reporting bias, other
bias) is presented in Figure 2. Most ratings in most domains for
the included studies were low risk, with the exception of high risk
of attrition bias in Morita 2017 as well as performance and detec-
tion bias due to lack of blinding. There was also unclear selection
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and performance bias in Julious 2016, unclear allocation bias in
Weiss 2010 and Morita 2017, and unclear selective reporting bias
in Johnston 2007.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All of the included studies were described as randomised. Each
study described random sequence generation in sufficient detail
in their report or in response to contact from the review authors
to warrant a rating of low risk of bias. All included studies used
computer-generated randomisation. However, information on al-
location concealment was incomplete for Weiss 2010 and Morita
2017, so this was rated unclear. Due to the nature of the inter-
vention it was not possible in the primary care study to blind par-
ticipating practices or children (Julious 2016), which might have
led to some performance bias since practices were able to choose
not to send the letter to individual patients or not to send any
letters at all. There may have been systematic bias in the children
or practices excluded in this manner, so we rated this study as at
high risk of bias. Almost a quarter of the intervention group did
not receive the intervention as intended. In contrast, since a letter
reminding parents to pick up asthma medications for their child
did not form part of usual care, all of the control group received
the control intervention (no letter) according to the protocol.
Blinding
Morita 2017 was an open, unblinded study and was therefore at
high risk of performance and detection bias. We found no evi-
dence of risk of bias related to blinding of children or observers
in the other pharmacological studies. These three studies were
described as double-blind, and study authors described measures
such as matched placebos to hide group allocation from children
and study personnel. In the primary care study (Julious 2016),
the risk of detection bias was low since outcome data were col-
lected via the Clinical Practice Research Datalink and designated
as “scheduled”, “unscheduled”, or “irrelevant” by an independent
adjudication panel comprised of experienced general practitioners
who were blinded to the treatment group. However, there may
have been some performance bias if coding of medical contacts
was influenced by general practitioners knowing whether or not
their practice was sending reminder letters. For this reasonwe rated
performance bias for this study as unclear.
Incomplete outcome data
Risk of bias due to high or unbalanced dropout was low across
all studies except Morita 2017. There was 14% attrition from the
pranlukast group after commencing the studymedication andonly
3% attrition from the placebo arm. All children in Johnston 2007
completed the study, and rates of treatment adherence and diary
card completion documenting outcome data were high. In Teach
2015a, the primary analysis was modified intention-to-treat, re-
stricted to children who were randomised, began study treatment,
and had one or more study contact during the outcome period. A
number of sensitivity analyses were presented including best- and
worst-case analyses and an analysis using multiple imputation of
missing data. There was good retention and similar dropout rates
and reasons between groups. Weiss 2010 also conducted a modi-
fied intention-to-treat primary analysis, including all childrenwho
received at least one dose of study medication and had a valid
measurement of the percentage of days with worsening asthma
during the study period, derived from at least seven days of diary
data. There was no imputation of missing data, but dropout rates
and reasons were similar between groups. In Julious 2016, with-
drawal rates were similar in the intervention and control arms.
The trialists felt imputation was not required since outcome data
were missing only where practices changed their computer system
to one that did not support data collection. This was assumed to
be unrelated to treatment allocation, however rates of withdrawal
were at least 25% in both groups.
Selective reporting
All named outcomes were reported in the published reports of
Weiss 2010, Teach 2015a, and Julious 2016; we rated these studies
as at low risk of bias. For Johnston 2007, it was unclear if all a
priori defined outcomes were reported. The protocol submitted
at trial registration stated that OCS use would be an outcome
considered separately fromunscheduledmedical contacts.Medical
contacts were reported as an outcome, but OCS use was not.
Although it was reported that all prescriptions of OCS occurred
as a consequence of an unscheduled visit to a doctor, it was not
clear whether all visits resulted in OCS prescription.
Other potential sources of bias
We identified no other sources of bias in any included study.
Effects of interventions
See: Summary of findings for the main comparison
Omalizumab compared to usual care for autumn asthma
exacerbations in children; Summary of findings 2 A boost
of inhaled corticosteroids compared to usual care for autumn
asthma exacerbations in children; Summary of findings 3
Leukotriene receptor antagonist compared to usual care for
autumn asthma exacerbations in children; Summary of findings
4 Behavioural intervention compared to usual care for autumn
asthma exacerbations in children
Primary outcomes
Proportion of children experiencing one or more asthma
exacerbations during the autumn period
OnlyTeach 2015a compared the number of children experiencing
asthma exacerbations exactly as defined in the primary outcome
of this review. Evidence relevant to this outcome is summarised
in Summary of findings for the main comparison and Summary
of findings 2. During the 90-day period from the first day of each
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child’s school year, the omalizumab intervention was associated
with exacerbation (worsening of asthma control requiring systemic
corticosteroids or hospitalisation) in 11.3% of children compared
with 21.0% in the placebo arm, odds ratio (OR) 0.48, 95% con-
fidence interval (CI) 0.25 to 0.92 (adjusted for study centre, dos-
ing schedule, and asthma severity step) (Analysis 1.1, Figure 3).
Considering those with stage 5 asthma, omalizumab was associ-
ated with a reduced odds of exacerbation (OR 0.37, 95% CI 0.17
to 0.81). In contrast, considering only steps 2 to 4 where chil-
dren were allocated to omalizumab, placebo, or a third arm of a
doubling of ICS, exacerbation rates were experienced by 8.4%,
12.7%, and 11.1% of children, respectively. The odds of exac-
erbation did not differ significantly between any pair of groups
(omalizumab versus placeboOR0.63, 95%CI 0.22 to 1.78; oma-
lizumab versus inhaled steroid boost OR 0.73, 95% CI 0.33 to
1.64; inhaled steroid boost versus placebo OR 0.86, 95% CI 0.32
to 2.30). However, when those experiencing a recent exacerbation
(during the four- to nine-month run-in ending four to six weeks
before school return) were considered separately from those with-
out a recent exacerbation, reduced odds of exacerbation were seen
across all severity steps 2 to 5 in the omalizumab group compared
to placebo (OR 0.12, 95% CI 0.02 to 0.64) and compared to ICS
boost across steps 2 to 4 (OR 0.05, 95% CI 0.003 to 0.98). For
those without an exacerbation during run-in, the odds of exacer-
bation were OR 0.88, 95% CI 0.35 to 2.18 compared to placebo
across steps 2 to 5 and OR 1.34, 95% CI 0.56 to 3.25 compared
to ICS boost across steps 2 to 4.
Figure 3. Forest plot of comparison: 1 Interventions for autumn exacerbations of asthma versus usual care,
outcome: 1.1 Exacerbations defined according to the review’s primary outcome.
Exacerbations reported according to alternative definitions
Johnston 2007 and Weiss 2010 considered the percentage of days
with worsening asthma symptoms as the primary outcome, whilst
Morita 2017 used a total asthma score based upon symptoms,
medication need, and healthcare utilisation. These outcomes were
not suitable for expression as an odds ratio. Johnston 2007 defined
worsening asthma symptoms as symptoms that were worse than
usual or needed extra asthma medication, or required an unsched-
uled visit to a doctor or treatment with oral corticosteroids; a 53%
reduction in days with worsening asthma symptoms was reported
compared with placebo during the 45-day intervention (3.9% ver-
sus 8.3%, P = 0.02). Boys aged 2 to 5 years showed greater benefit
from montelukast than did older boys, whereas among girls the
treatment effect was most evident in 10- to 14-year-olds. The pro-
portion of participants reporting one or more unscheduled visits
to a doctor for asthma symptoms was markedly reduced in the
montelukast group compared to the placebo group (4.1% versus
14.6%; OR 0.25, 95% CI 0.08 to 0.79), and it was reported that
all prescriptions of OCS for asthma exacerbation occurred as a
consequence of an unscheduled visit to a doctor. Weiss 2010 de-
fined worsening asthma symptoms as one or more of the following
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actions: increased beta-agonist use; increased daytime symptoms
score; being awake ’all night’ due to asthma; increased ICS use;
OCS rescue; or unanticipated visits to a doctor, emergency depart-
ment, or hospital for asthma. Analyses were adjusted for treatment,
school start date, investigator site type, ICS use at entry, age, and
sex. We found no significant difference in worsening symptoms
between groups or for any component of this outcome, including
OCS use (26.0% versus 30.3%; OR 0.79, 95% CI 0.59 to 1.06)
and unanticipated medical contacts (11.8% versus 14.7%; OR
0.77, 95% CI 0.53 to 1.13). There was a consistent direction of
effect favouring the intervention for five of the six outcomes, but
none reached significance. Prespecified subgroup analyses found
significantly fewer days of worsening symptoms in boys and in
children aged 10 to 14 years, although interaction terms for age
and gender were non-significant. Morita 2017 based total asthma
score on asthma symptoms, need for increased asthmamedication,
unscheduled physician visit or OCS; an adjustment was made in
multivariable analysis for ICS use. There were no significant differ-
ences between pranlukast and control group in total asthma score
(5.5 versus 7.8, P = 0.35) or days of worsening asthma symptoms
(1.5 versus 1.8, P = 0.67). Significantly lower asthma scores and
number of colds were seen for boys age one to five years. A higher
number of colds and days of fever were seen in the control group
compared to the pranlukast group, but only the latter reached sig-
nificance (P = 0.06 and P = 0.04, respectively). Unscheduled visits
to a doctor or OCS did not differ between groups (5.9% versus
8.6%; OR 0.67, 95% CI 0.16 to 2.80, Analysis 1.2, Figure 4).
Evidence relevant to LTRA-based interventions is summarised in
Summary of findings 3.
Figure 4. Forest plot of comparison: 1 Interventions for autumn exacerbations of asthma versus usual care,
outcome: 1.2 Exacerbations defined according to study-specific definitions.
In Julious 2016, exacerbations were not directly measured, but
numbers of unscheduled contacts were reported as a proxy for this,
and the study also reported unscheduled contacts coded with a res-
piratory diagnosis. Neither outcome significantly favoured the in-
tervention.Datawere reported between September andDecember
rather than for the three months following school return; during
September toDecember unscheduled contacts for a respiratory di-
agnosis were recorded for a greater proportion of children receiving
the intervention letter than for those in the control group (18.4%
versus 16.7%; OR 1.13, 95% CI 0.95 to 1.33), but this differ-
ence was not significant (Summary of findings 4). Unscheduled
contacts for any diagnosis also did not differ significantly between
the intervention and usual care groups (80.1% versus 79.1%; OR
1.10, 95% CI 0.96 to 1.26). The primary outcome period for this
study was September; during this period no significant between-
group differences were reported for the proportion of children
for whom any medical contact or any unscheduled contact was
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recorded. Unscheduled contacts for a respiratory diagnosis were
recorded in significantly higher numbers in the intervention than
in the usual care arm (5.3% versus 4.2%; OR 1.30, 95% CI 1.03
to 1.66). Analyses were modelled using age, sex, number of con-
tacts the previous September and the trial arm as fixed-effect, and
the design/cluster effect of general practice as random-effects. The
study authors suggested that contacts following the intervention
might have occurred as a result of appointments needed to assess
children’s need for preventer medication.
Asthma exacerbations and the period during which children were
considered at risk of exacerbation after school return were defined
differently in each trial. Moreover, the interventions trialled rarely
used the same approach or medication. For these reasons, we lim-
ited meta-analysis to studies with comparable interventions based
upon seasonal administration of montelukast. Even amongst these
three trials, participant populations and outcomes varied slightly:
in Johnston 2007 the intervention period was fixed for 45 days
from 1 September, whilst in Weiss 2010 the intervention period
was for eight weeks from the night before each child’s school re-
turn, and in Morita 2017 children were randomised two to six
weeks before a fixed 60-day study period starting from 15 Septem-
ber. The participant populations in these trials differed according
to both age and asthma severity: participants were both younger
and more likely to be receiving ICS in Johnston 2007 and Morita
2017 than in Weiss 2010. Despite the higher proportion of chil-
dren receiving ICS at trial outset in Johnston 2007 and Morita
2017, higher rates of oral steroid prescription occurred in Weiss
2010. It was not possible to assess the review’s primary outcome
in these studies since, although each separately reportedOCS pre-
scription and unscheduledmedical contact, the proportion of chil-
dren with an exacerbation needing hospitalisation orOCSwas not
reported. Where evidence was based on single studies, the quality
was moderate, downgraded due to small numbers of participants
randomised or use of an indirect outcome (unscheduled respira-
tory contacts in Julious 2016 rather than hospitalisation or oral
steroid requirement).When results from Johnston 2007 andWeiss
2010 were included in a random-effects model, the odds ratio for
unscheduled medical contacts was 0.50, 95%CI 0.17 to 1.46. We
judged the evidence to be of low quality due to poor consistency
between studies and concerns about the indirect outcome of un-
scheduled medical contact, the threshold for which appeared to
differ between studies. The I² statistic was 70%, so we deemed a
fixed-effect model to be inappropriate.
Secondary outcomes
Hospital and paediatric intensive care unit admissions and
asthma-related deaths
Although Johnston 2007, Weiss 2010, Teach 2015a, and Morita
2017 reportedmedical contact data, including hospital admission,
no study presented data on hospitalisation or paediatric intensive
care unit admission separately from total unscheduled contacts or
OCS use. No study reported any asthma-related deaths.
Asthma control, quality of life, and impact on schooling
No study reported asthma control measured by a standardised tool
(e.g. Childhood Asthma Control Test (cACT) or Asthma Control
Test (ACT)). Weiss 2010 mentioned increased symptom score,
but the scale on which this was measured was not defined. We
found no significant between-group differences for this outcome.
No study measured asthma-related quality of life or absence from
school (or employment for those beyond school age).
Adverse events
In the pharmacological studies, there was no evidence that either
adverse events or serious adverse event rate differed between the
intervention and the usual care group. Adverse events were not
formally reported in the primary care intervention study (Julious
2016). Morita 2017 reported that no children discontinued study
medication due to an adverse event, and the authors of this study
confirmed that no adverse events occurred in either group. In
Johnston 2007, minor adverse events occurred in 20.4% of chil-
dren in the montelukast group and in 28.1% of children in the
placebo group (OR 0.66, 95% CI 0.34 to 1.27) (Summary of
findings 3). Adverse events caused two children to discontinue the
placebo: one child experienced behavioural change and the other
tiredness and appetite changes. A significant behavioural disor-
der requiring emergency treatment was identified in a participant
from themontelukast group at the follow-up interview.No adverse
events were described as serious. Teach 2015a reported adverse
events during the period between randomisation and 30 days after
the end of the intervention period. Of those children receiving at
least one dose of the study drug, 54.5% in the omalizumab arm
and 54.8% in the placebo arm experienced an adverse event (OR
0.99, 95% CI 0.61 to 1.58, Analysis 1.3, Figure 5) (Summary of
findings for the main comparison). Considering only children el-
igible for the ICS boost (steps 2 to 4), one or more adverse events
were reported by 43.5% of children in the ICS boost arm and
53.3% of children in the placebo arm (OR 0.67, 95% CI 0.34 to
1.33). Two serious adverse events occurred: a seventh nerve palsy in
the placebo group and an episode of anaphylaxis in the ICS boost
arm (Summary of findings 2). In Weiss 2010, 33.9% of children
in themontelukast group and 33.6% of those in the placebo group
reported at least one adverse event (OR 1.02, 95% CI 0.79 to
1.30) (Summary of findings 3); the most common adverse events
were upper respiratory tract disorders and infections. Four serious
adverse events occurred in the intervention group and one in the
placebo group (0.7% versus 0.2%). Consequently, there was no
evidence in any study that total adverse events occurred more fre-
quently in the intervention than in the usual care arm. Moreover,
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we found no evidence of a significant difference between these
groups when data from the montelukast studies were pooled in a
random-effects model (OR 0.91, 95%CI 0.63 to 1.32; I² = 32%).
However, significantly more children experienced local adminis-
tration site reactions in the intervention group in Teach 2015a
compared to the usual care group (15.3% versus 6.5%, P = 0.03).
We graded the quality of the evidence for this outcome as high
for the pooled montelukast data and moderate for omalizumab or
steroid boost intervention, downgrading the evidence due to the
imprecision inherent to low participant numbers.
Figure 5. Forest plot of comparison: 1 Interventions for autumn exacerbations of asthma versus usual care,
outcome: 1.3 Adverse effects.
Subgroup analyses
We had planned analyses separating studies of pharmacological
interventions from studies of non-pharmacological interventions,
and to consider separately those with mild-to-moderate disease
and those with severe asthma. Due to the low numbers of stud-
ies identified and the likely heterogeneity introduced by combin-
ingdifferent pharmacological interventions, the planned subgroup
analyses were not justified. We identified only one non-pharma-
cological study, and baseline medication use and asthma severity
were not always well described.
Sensitivity analyses
Wehadplanned an analysis including only studieswithoutmissing
data and an analysis excluding cluster-randomised trials. Due to
the low numbers of studies identified, these subgroup analyses
were not possible.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
A boost of inhaled corticosteroids compared to usual care for autumn asthma exacerbations in children
Patient or population: autumn asthma exacerbat ions in children
Setting: community
Intervention: a boost of inhaled cort icosteroids
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with a boost of in-
haled corticosteroids
Exacerbat ions
assessed with: hospital
admission or oral cor-
t icosteroid requirement
asthma stages 2-4
follow-up: 90 days
127 per 1000 111 per 1000
(44 to 251)
OR 0.86
(0.32 to 2.30)
173
(1 RCT)
⊕⊕⊕©
MODERATE 1
Absolute ef fects calcu-
lated using control risk
of 12.7% f rom Teach
2015a.
Adverse events
assessed with: number
of children experienc-
ing 1 or more adverse
events asthma stage 2-
4
follow-up: 17 to 19
weeks
533 per 1000 434 per 1000
(280 to 603)
OR 0.67
(0.34 to 1.33)
176
(1 RCT)
⊕⊕⊕©
MODERATE 1
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded once for imprecision because few children studied.
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Leukotriene receptor antagonist (LTRA) compared to usual care for autumn asthma exacerbations in children
Patient or population: autumn asthma exacerbat ions in children
Setting: community
Intervention: LTRA
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with montelukast
Exacerbat ions
assessed with: oral cor-
t icosteroid or hospitali-
sat ion
- - - - - Not reported
Exacerbat ions
assessed with: un-
scheduled medical con-
tacts
follow-up: range 45
days to 8 weeks
146 per 1000 79 per 1000
(28 to 200)
OR 0.50
(0.17 to 1.46)
1326
(2 RCTs)
⊕⊕©©
LOW 12
Absolute ef fects calcu-
lated using control risk
of 14.6%f rom Johnston
2007.
Adverse events
assessed with: number
of children experienc-
ing 1 or more adverse
events
follow-up: range 45
days to 10 weeks
328 per 1000 307 per 1000
(235 to 392)
OR 0.91
(0.63 to 1.32)
1326
(2 RCTs)
⊕⊕⊕⊕
HIGH
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial
2
2
In
te
rv
e
n
tio
n
s
fo
r
a
u
tu
m
n
e
x
a
c
e
rb
a
tio
n
s
o
f
a
sth
m
a
in
c
h
ild
re
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded once for inconsistency because asthma severity of children dif fered between included studies, and thresholds
for medical contact or oral steroids appeared to dif fer between studies.
2Downgraded once for indirectness since studies contained no data on hospitalisat ion and need for oral steroids, so
unscheduled medical contacts used as a proxy.
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Behavioural intervention compared to usual care for autumn asthma exacerbations in children
Patient or population: autumn asthma exacerbat ions in children
Setting: community
Intervention: behavioural intervent ion
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care Risk with behavioural
intervention
Exacerbat ions
assessed with: oral cor-
t icosteroid or hospitali-
sat ion
- - - - - Not reported
Exacerbat ions
assessed with: un-
scheduled contact for
respiratory diagnosis
follow-up: 4 months
167 per 1000 185 per 1000
(160 to 211)
OR 1.13
(0.95 to 1.33)
10,481
(1 RCT)
⊕⊕⊕©
MODERATE 1
Absolute ef fects calcu-
lated using control rate
of 16.7% f rom Julious
2016.
Adverse events - - - - - Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect24
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1Downgraded once for indirectness because studies contained no data on hospitalisat ion and need for oral steroids, so
unscheduled contacts for a respiratory diagnosis used as a proxy outcome.
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D I S C U S S I O N
Summary of main results
Five randomised controlled trials met the inclusion criteria. Three
were double-blinded pharmacological studies; one was an open
pharmacological study; and the remaining study was a cluster-ran-
domised trial of a public health intervention delivered in primary
care. Three studies compared seasonal LTRA administration to a
placebo, and one study compared seasonal omalizumab or an ICS
boost to placebo. The primary care intervention was a letter sent
to parents of children with asthma explaining the need to have ad-
equate inhaled medication ready at the start of the autumn school
term.
Two pharmacological studies reported a reduction in asthma ex-
acerbations associated with the intervention. A 50% reduction
(from 21% to 11.3%) in the proportion of children experienc-
ing an exacerbation was found in allergen-sensitised children with
mild-severe asthma and IgE > 30 IU/mL receiving omalizumab
compared to placebo (Teach 2015a) (Summary of findings for
the main comparison). In subgroup analyses within this study, a
reduction in exacerbation risk was demonstrated in children re-
ceiving treatment for severe asthma where there is little scope for
additional therapy other than OCS and in those with a recent
exacerbation. A 70% reduction (from 14.6% to 4.1%) was found
in children with moderate-severe asthma receiving montelukast
(Johnston 2007). However, neither a second larger trial of mon-
telukast (Weiss 2010), nor pooled data from both studies found
evidence for a significant between-group difference in the propor-
tion of children experiencing exacerbations (Summary of findings
3). Exacerbations requiring admission or a course ofOCSwere not
reported in the primary care intervention study. However, there
was no evidence that the proportion of participants who had at
least one unscheduled medical contact between September and
December differed between the intervention and the control group
(Julious 2016) (Summary of findings 4).Of the planned secondary
outcomes, we could only assess adverse events and serious adverse
events; there was no evidence of a significant difference between
intervention and usual care groups for either of these outcomes.
Overall completeness and applicability of
evidence
Due to the small number of studies identified and variation in their
inclusion criteria, interventions, and outcomes, it was not possible
to perform subgroup analysis or sensitivity analyses. Insufficient
data for subgroup analyses prevented us from reaching conclu-
sions about the relative efficacy of pharmacological and non-phar-
macological interventions or about efficacy according to asthma
severity or other characteristics such as age or gender. Whilst all
included studies reported asthma exacerbations or worsening of
symptoms, none considered the burden associated with worsen-
ing asthma symptoms in terms of absence from education or em-
ployment or used a validated measure of asthma control or quality
of life. Consideration of these important clinical outcomes would
have increased the applicability for a clinical audience. Outcomes
such as paediatric intensive care unit admission and asthma-re-
lated death are rare and were not reported in the included stud-
ies. All included studies were conducted in the Northern Hemi-
sphere. Inclusion of studies from the Southern Hemisphere would
increase the generalisability of the results. Similarly, it may not
be possible to generalise the findings of Teach 2015a beyond the
largely minority, low-income population in which this study was
conducted or to children with asthma who are not allergen-sen-
sitised. Lack of clarity regarding the efficacy of strategies aiming
to prevent autumn exacerbations is reflected in current guidelines.
Whilst the Global Initiative for Asthma guidelines recognise the
autumn season as a risk period for exacerbation, and seasonality of
symptoms is mentioned in the British Thoracic Society/Scottish
Intercollegiate Guidelines Network guideline for the management
of asthma, current guidelines do not offer management advice to
tackle this problem (BTS 2016; GINA 2017).
Quality of the evidence
The five included studies randomised 14,252 children to receive
either an intervention designed to reduce asthma exacerbations
in children during autumn after school return or to usual care.
The largest study randomised 12,179 children, and the smallest
194. Childrenwere predominantly school-age, although two stud-
ies enrolled a small number of preschool-aged children (Johnston
2007; Morita 2017). Because the interventions investigated dif-
fered between studies, inconsistencies between the studies’ results
might reflect the relative efficacy of the interventions. For exam-
ple, greater efficacy of pharmacological than non-pharmacological
interventions might explain why the intervention was found to be
superior to placebo in Johnston 2007 and Teach 2015a and also
approached significance for many outcomes in Weiss 2010 and
Morita 2017, but no outcome favoured the intervention in Julious
2016. However, asthma severity and exacerbations also varied be-
tween and within studies. Differences in rates of asthma exacer-
bations did not always reflect difference in baseline severity. For
example, higher rates of OCS use were reported in the population
studied by Weiss 2010 than in those studied by Johnston 2007
and Morita 2017, despite lower baseline severity in the former
study. Worsening asthma symptoms, inclusion criteria, interven-
tion period, and outcomes were not uniformly defined across stud-
ies. Weiss 2010, Julious 2016, and Morita 2017 included children
with relatively mild asthma, and this might have limited the po-
tential for the interventions in these studies to reduce exacerbation
rates below an already low baseline. Moreover, as a consequence
of using routinely collected data, the study by Julious 2016 was
also limited by considerable uncertainty around the adjudication
of some of the contacts as scheduled, unscheduled, or irrelevant.
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We assessed the quality of the evidence in this review using
GRADEpro software and have presented this information in
’Summary of findings’ tables. Overall, the evidence for exacerba-
tion outcomes ranged from low to moderate according to the na-
ture of the intervention, whilst the quality of the adverse event
data was moderate or high. We downgraded evidence due to the
small number of studies included and hence wide confidence inter-
vals. Moreover, interventions differed qualitatively between stud-
ies, and in some cases surrogate outcomes were reported.
When pooling data from the montelukast studies, we used inverse
variance random-effects modelling for the exacerbation outcome
due to constraints in the extracted data. While we would have pre-
ferred Mantel-Haenszel modelling for both models, since it pro-
vides better estimates for infrequent events, this was not possible
to implement with Review Manager 5 and the data available.
Potential biases in the review process
We used standard Cochrane methodology to conduct this review.
We performed extensive literature searches and did not limit study
selection by language of publication. Two review authors inde-
pendently screened published data and conference abstracts. Dis-
crepancies were resolved through discussion or, if necessary, by
consultation with a third review author. Given our use of a thor-
ough search strategy, it is unlikely that the study selection pro-
cess missed any available published studies. We recognise that the
clinical problem of asthma exacerbations associated with school
return is complex and that consistent terminology does not exist
to describe this problem or interventions designed to prevent it.
To mitigate against this problem, the search terms used included
’February’, ’autumn’ or ’fall’ and ’seasonal’ in addition to ’Septem-
ber’. Two review authors independently extracted study character-
istics and numerical data. Any discrepancies were resolved through
discussion or, if necessary, by consultation with a third review au-
thor. Similarly, two review authors independently made decisions
about risk of bias, resolving any discrepancies through discussion
or, if necessary, by consultation with a third review author. We
also attempted to contact all study authors to obtain additional
information about outcomes and to clarify study methods to en-
sure accurate ’Risk of bias’ decisions. We received three detailed
replies and additional data from one study author, while one au-
thor was unable to provide the requested information relating to
risk of bias. Review authors reported no conflicts of interest.
Agreements and disagreements with other
studies or reviews
We identified no other systematic reviews relating to this issue.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found evidence from one relatively small study suggesting that
add-on seasonal omalizumab treatment commencing four to six
weeks before school return might reduce asthma exacerbations in
allergen-sensitised children during the annual period of highest
risk. Subgroups demonstrating benefit were children with severe
asthma and those with frequent exacerbations. We found no evi-
dence that this strategy is associatedwith significantlymore adverse
effects, other than administration site reactions, than placebo. Al-
though results from one study suggest seasonal montelukast might
reduce autumn exacerbations, there was no evidence for a reduc-
tion in exacerbations from either two subsequent trials based on
leukotriene receptor antagonist therapy or pooled data from trials
of montelukast. We found no data upon which to judge the effect
of this or other interventions on asthma control, quality of life, or
asthma-related death.
Implications for research
Further investigation of interventions to reduce the risk of asthma
exacerbations in children after they return to school in the au-
tumn is needed to reduce clinical impact and disease burden and
also to better understand the mechanisms underlying asthma ex-
acerbations. Analysis of interferon release from peripheral blood
mononuclear cells of children receiving omalizumab within the
Teach 2015a study suggest that omalizumab might improve the
interferon response to rhinovirus, and in turn this might be one
mechanism whereby exacerbations are reduced. Omalizumab ap-
peared to be most effective in those with severe asthma, for whom
treatment options are limited, and those at greatest risk of exacer-
bation. Whilst a seasonal approach would be cheaper than year-
round treatment, it remains expensive and can be painful to ad-
minister. Consequently, there is a need to identify relatively low-
expense interventions that could be useful to all those with asthma.
To date, no studies have been conducted in the Southern Hemi-
sphere, and only a limited number of pharmacological and non-
pharmacological strategies have been evaluated. In future studies,
definitions of exacerbations should be provided, and where possi-
ble standardised. In order to support subgroup analysis according
to asthma severity, children in future trials should be well charac-
terised with respect to baseline asthma severity and previous exac-
erbation history, as well as age and gender.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Johnston 2007
Methods Study design: randomised, double-blind, placebo-controlled trial.
Aim: to determine whether montelukast, added to usual asthma therapy, would reduce
days with worse asthma symptoms and unscheduled physician visits of children during
the September epidemic
Study centres and method of recruitment: recruited through advertising and through
clinical practices in Hamilton and Brantford, Canada
Dates of study: 1 September 2005 to 15 October 2005.
Run-in period: no run-in period.
Duration of participation: 45 days.
Consent: approved by the research ethics board at St. Joseph’s Healthcare Hamilton.
Informed consent from parents and assent from appropriately aged children
Power: a 40% reduction was expected in days with worse asthma symptoms in the
montelukast group based upon results of a pilot study. Based upon 80% power and a 0.
05 significance level, a sample-size requirement of 88 per group was estimated. A 10%
dropout rate was allowed for, so the final sample requirement was 97 per group
Imputation of missing data, i.e. assumptions made for ITT analysis: all randomised
children completed the study and were included in analysis
Participants Age (mean, range): not reported, 2 to 14 years.
Gender: 65.0% male.
Asthma severity: not explicitly mentioned, but 90% required inhaled corticosteroids
(likely moderate to severe)
Diagnostic criteria: physician-diagnosed asthma.
Number recruited: 196
Number randomised (intervention, control): 98, 96
Number completed (intervention, control): 98, 96
Number analysed (intervention, control): 98, 96
Withdrawals: 100% completed, no withdrawals.
Inclusion criteria: 2 to 14 years old; physician-diagnosed asthma needing a rescue
inhaler in the last year; missing ≥ 1 day from school because of asthma in the last year or
having significant limitation of normal activity; having a history of asthma exacerbations
associated with apparent respiratory viral infections; ability to communicate in English
Exclusion criteria: significant cardiorespiratory comorbidity; using an LTRA; using
regular OCS medication; asthma exacerbation in the month before study inception
Interventions Intervention: montelukast age-specific dose from 1 September to 15 October
Comparison: matched placebo.
Concomitant medication: usual therapy.
Excluded medication: already on montelukast.
Outcomes Primary outcome: percentage of days with worsening asthma symptoms during the
intervention period (worsening symptoms defined as symptoms that were worse than
usual or needed extra asthma medication, or requiring an unscheduled visit to a doctor
or treatment with oral corticosteroids)
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Johnston 2007 (Continued)
Secondary outcome: number of unscheduled care visits.
Time points measured: daily, then at the end of the study.
Primary outcome result: the montelukast group experienced a 53% reduction in days
with worse asthma symptoms compared with placebo (3.9% vs 8.3%, P = 0.02)
Secondary outcome results: the montelukast group experienced a 78% reduction in
unscheduled physician visits for asthma (4 for montelukast vs 18 for placebo, P = 0.011)
Adverse events: minor adverse events occurred in 25 children in the montelukast group
and in 35 children in the placebo group. 2 children discontinued study medication due
to adverse events, 1 due to a personality change and 1 with change in appetite and
increased tiredness; both children were taking placebo. The trial code was not broken,
and symptom recording was continued. Another significant event was identified at the
follow-up interview after a child assigned to receive montelukast required emergency
treatment for acute behaviour disorder
Notes Funding: Merck Frosst Canada Ltd.
Subgroups: subgroup analyses were exploratory risk of asthma worsening intervention
vs control:
• regular ICS users OR 0.13 95% CI 0.03 to 0.51
• no ICS use OR 0.14, 95% CI 0.04 to 0.53
• intermittent ICS use OR 0.37, 95% CI 0.10 to -1.31
• regular ICS/LABA use OR 0.44, 95% CI 0.11 to 1.75
• intermittent ICS/LABA use OR 1.24, 95% CI 0.31 to 4.89
• boys 2 to 5 years OR 0.03, 95% CI 0.01 to 0.21
• boys 6 to 9 years OR 0.27, 95% CI 0.09 to 0.87
• boys 10 to 14 years OR 0.81, 95% CI 0.24 to 2.77
• girls 2 to 5 years OR 1.29, 95% CI 0.18 to 9.1
• girls 6 to 9 years OR 0.68, 95% CI 0.13 to 3.45
• girls 10 to 14 years OR 0.17, 95% CI 0.05 to 0.52
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
schedule. Randomly assigned in blocks of
4 according to gender and age
Allocation concealment (selection bias) Low risk Randomisation schedule described as “con-
cealed” and generated by an individual “not
otherwise involved in the study”. Mech-
anism of concealment described as based
upon identical containers issued by third
party (further information supplied by au-
thors)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded. Intervention drug and
placebo prepared by Merck Frosst, no rea-
son to suspect parent or child could iden-
tify intervention drug from placebo
34Interventions for autumn exacerbations of asthma in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Johnston 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Given the use of a placebo, unlikely that
the assessors would have knowledge of
participant group. Subjective participant-
reported parent-assessed symptoms and
questionnaire used to assess other out-
comes; these could have been affected if
blinding inadequate, but no reason to sus-
pect placebo led to incomplete blinding.
Physician validated unscheduled care
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat primary analysis, 100%
children completed the trial and returned
99.7% diary data. Adherence good in
both groups (91.7% intervention vs 93.2%
placebo)
Selective reporting (reporting bias) Unclear risk Unclear whether all prespecified outcomes
included in the analysis
Other bias Low risk Nobaseline differences between groups, ex-
cept more lifetime hospitalisations: 37.8%
intervention vs 25.0% placebo
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Julious 2016
Methods Study design: cluster-randomised controlled trial.
Aim: to assess the impact of anNHS-delivered public health interventiononunscheduled
medical contacts in children with asthma during September and to perform a health
economic analysis of the intervention
Study centres and method of recruitment: 142 UK general practices. Recruitment
predominantly via the Clinical Practice Research Datalink (CPRD). A recruitment pack,
including study information and an expression of interest form, was sent by post to the
preferred contact at the practice to all 433 practices contributing to CPRD in England
and Wales at the time of recruitment. Non-responding practices were sent a reminder
e-mail, followed by a second reminder e-mail and then final reminders by e-mail and
post. Some practices were also contacted by telephone, by CPRD or the study team at
the Sheffield Clinical Trials Research Unit. Practices returned the completed expression
of interest form, confirming or updating as necessary the information about the practice
held by CPRD. Responses were tracked by CPRD to ensure practices that had replied
were not contacted again. The expressions of interest were then forwarded to the study
team to contact practices
Dates of study: 29 July 2013 to 30 September 2014.
Run-in period: none.
Duration of participation: intervention commenced the week of 29 July 2013.
Unscheduled care outcomes measured: September 2013, September to December
2013, September 2013 to August 2014, September 2014
Health economic outcomes measured: 1 August 2013 to 31 July 2014.
Consent: ethics approval for the study was given by South Yorkshire Research Ethics
Committee on 25 October 2012 (reference number: 12/YH/04). NHS permissions to
conduct the study were obtained for all the primary care trusts in England and health
boards in Wales
Power: the study was designed to detect a difference of 5% (30% vs 25%) with 90%
power and a 2-sided significance level of 5%, with an intraclass correlation of 0.03 to
account for clustering. Based on this, 70 practices were estimated to be required per arm.
It was expected that the sample size of 140 practices would equate to approximately 14,
000 school-aged children with asthma
Imputation of missing data, i.e. assumptions made for ITT analysis: analyses of
effectiveness were performed as both ITT andPP, with the ITTbeing primary. If practices
stopped submitting data to the CPRD before the end of a given follow-up period, they
were excluded from all analyses for that time period. The health economic analyses were
based on the PP population. ITT analyses included all practices for which data were
obtained by study period. The PP analyses were the subset of children in the ITT analyses
to whom the intervention was delivered as intended by the protocol (i.e. individuals or
practices not receiving a letter were excluded from PP analyses)
Participants Age (mean, range): 10.5 years, 5 to 16 years. 4-year-old children analysed separately
Gender: 60.0% male.
Asthma severity: majority most likely mild (severity data not presented).
Diagnostic criteria: coded diagnosis of asthma. Eligible participants identified in accor-
dance with pre-agreed diagnostic codes for asthma by the CPRD
Number recruited: 12,179
Number randomised (intervention, control): 5917, 6262
Number completed (intervention, control): 4411, 4438
Number analysed (intervention, control): 4411, 4438
(Note: figures above are for completing the entire trial until September 2014. ITT
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analyses of outcomes in September 2013, the primary outcome period, were based on
5305 intervention and 5586 control participants.)
Withdrawals: from experimental group: discontinued intervention withdrawal before
30 September 2014: 13 practices, 506 children. From control group: discontinued in-
tervention withdrawal before 30 September 2014: 18 practices, 1824 children
Inclusion criteria: aged between 4 and 16 years on 1 September 2013; coded diagnosis
of asthma; prescribed asthma medication March 2012 to March 2013
Exclusion criteria: aged 4 years or under on 1 September 2013 or 16 years or over on
31 August 2013; not considered appropriate for this intervention by GP; not receiving
asthma medication; coexisting neoplastic disease
Interventions Intervention: NHS-delivered public health intervention (a letter sent from the GP to
parents/carers of school-aged children with asthma reminding of the importance to
take medications and the need to get sufficient medication sent out during the week
commencing 29 July 2013)
Comparison: no letter, control arm continue with standard care as usual, no other
activity required
Concomitant medication: usual therapy.
Excluded medication: none.
Outcomes Primary outcome: proportion of childrenwith unscheduled contacts in September 2013
Secondary outcomes: number/proportion/time to first unscheduled contact;
number/proportion/time tofirst unscheduled contacts for respiratory diagnosis; number/
proportion/time to first all medical contacts; proportion scheduled contacts; number
collecting prescriptions; QALYs gained; and NHS costs
Time points measured:
• medical contacts/unscheduled September 2013
• medical contacts/unscheduled September to December 2013
• medical contacts/unscheduled/time to first September 2013 to August 2014
• medical contacts/unscheduled September 2014
• prescription uptake and scheduled care
• scheduled contacts and prescription uptake August 2013
• scheduled contacts August 2013 to July 2014
• scheduled contacts and prescription uptake August 2014
• health economic outcomes 1 August 2013 to 31 July 2014
Primary outcome result: proportion of children with unscheduled contacts in Septem-
ber intervention vs control: 45.2 vs 43.7; OR 1.09, 95% CI 0.96 to 1.25
Secondary outcome results: intervention vs control multiple outcomes and subgroups
assessed, most outcomes no significant difference between groups. Proportion prescrip-
tions August 2013: OR 1.43, 95% CI 1.24 to 1.64; number of scheduled contacts per
child August 2013: OR 95%CI 1.13, 0.84 to 1.52. No significant difference in unsched-
uled contacts September to December 2013, September 2013 to August 2014. Mean
cost saving across the base case of GBP 36.07 per child and 96.3% probability that the
intervention is cost-saving. Intervention resulted in a QALY loss in 82.9% of samples
and a mean loss of 0.00017 QALYs
Adverse events: not reported.
Notes Funding: National Institute for Health Research.
Subgroups: the primary outcome was similar for 5- to 16-year-old children who had
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been prescribed preventative steroids compared to all 5- to 16-year-old children. Among
children aged under 5 years, the differences were larger, and of borderline statistical sig-
nificance, with the intervention being associated with more unscheduled visits for all
subgroups. In all cases, the effect among the PP populationwas greater than that observed
in the ITT population. Post hoc analyses demonstrated that for those who collected a
prescription within the last 3 months, there was no difference in unscheduled contacts
in September (55.2% vs 54.3% control), whilst for those whose last prescription was
collected 3 to 6 months ago, there was an excess of unscheduled contacts in September
(42.1% vs 39.7% control). (Data confirmed with study author since they differed be-
tween the summary and the main text of the report.)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by practice, stratified by size
(confirmed by communicationwith author
that the study statistician had no informa-
tion about practices prior to randomisation
other than list size)
Allocation concealment (selection bias) Unclear risk Sequence generated by 1 of 2 trial statisti-
cians, then revealed to study manager and
research assistant. Statisticians had no in-
formation about practice other than list
size. However, characteristics of individual
practices influenced whether the interven-
tion was enacted or not
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study team and participants unblinded;
this might have affected coding of contacts.
Study team had no influence on data cap-
ture. Individual practices could choose not
send the letter at all or not to send to se-
lected patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Collected via CPRD. Contacts designated
as “scheduled”, “unscheduled”, and “irrel-
evant” based on an independent adjudica-
tion panel comprised of experienced GPs
who were blinded to the treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data due to change in
computer system; presumed to be missing
completely at random so no imputation.
However, this was at least 25% in each
group
Selective reporting (reporting bias) Low risk All outcomes reported.
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Other bias Low risk No baseline difference in age, gender, and
practice size
Morita 2017
Methods Study design: randomised, open study.
Aim: to investigate whether pranlukast added to usual asthma therapy in Japanese chil-
dren during the autumn reduces asthma exacerbations. The effects of age and sex on the
efficacy of pranlukast were also evaluated
Study centres andmethod of recruitment:multiple clinical sites in Chiba, Japan. Study
participants were recruited between July 2007 and August 2007 through advertising and
from the clinical practices in Chiba, Japan
Dates of study: 15 September 2007 to 14 November 2007.
Run-in period: from recruitment until 15 September 2007.
Duration of participation: 60 days in addition to run-in period.
Consent: the investigation was approved by the Research Ethics Board of Chiba Uni-
versiy, Chiba (approval number: 631). Written informed consent was obtained from the
parents of all participants and child assent when appropriate
Power: no a priori calculation.
Imputation of missing data, i.e. assumptions made for ITT analysis: 13.6% of chil-
dren excluded after randomisation in the pranlukast group (2.8% placebo), but no im-
putation made
Participants Age (mean, range): 5.5 years (not reported but supplied by author), 1 to 14 years
(divided into 2 age groups: 1 to 5 years and 6 to 14 years)
Gender: 62.8% male.
Asthma severity: 54.5% required inhaled corticosteroids.
Diagnostic criteria:physician-diagnosed asthma.Asthmawas diagnosed by primary care
doctors based on the Japanese paediatric guidelines for the treatment and management
of bronchial asthma 2005
Number recruited: 204
Number randomised (intervention, control): 102, 102
Number completed (intervention, control): 59, 72
Number analysed (intervention, control): 51, 70
Withdrawals: 43 from intervention group and 30 from control group excluded before
trial due to respiratory symptoms or insufficient diary recording by caregivers, or both,
during the observation period. 8 from intervention group and 2 from control group
excluded during the study period due to poor compliance or insufficient diary recording
by caregivers, or both
Inclusion criteria: age 1 to 14 years old, physician-diagnosed asthma needing a rescue
inhaler in the last year, with a history of asthma exacerbations associated with apparent
respiratory viral infections. Children who had been treated with LTRA were included
after 14-day washout period
Exclusion criteria: significant cardiorespiratory comorbidity; using regular oral corti-
costeroid; or had an asthma exacerbation in the month before treatment with pranlukast
started. Children who had respiratory symptoms or problems with diary recording dur-
ing observation, or both, were excluded from the study
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Interventions Intervention: regular pranlukast, an LTRA. 7 mg/kg, twice daily, in addition to their
usual asthma therapy
Comparison: usual therapy.
Concomitant medication: intervention taken in addition to usual asthma therapy. No
restriction, but children who had been treated with LTRA were included after a 14-day
washout period
Excluded medication: no restriction, but 14-day washout of LTRA.
Outcomes Primary outcome: total asthma score calculated during 8 weeks. Total asthma score was
evaluated as follows: a blue sticker (score, 0) was applied on days when a child had no
asthma symptoms; a green sticker (score, 1) indicated mild asthma symptoms; a yellow
sticker (score, 2) indicated symptoms that were worse than usual or needed extra asthma
medication, and an orange sticker (score, 3) was applied if a child’s breathing symptoms
required an unscheduled visit to a physician or treatment with oral corticosteroids
Secondary outcomes: days with worse asthma symptoms, number of colds, and days
with fever. Dayswith worse asthma symptomswere defined as those with either an orange
or a yellow sticker. A fever was defined as a temperature exceeding 38 °C. A “cold” was
defined as the presence of more than 2 consecutive purple stickers indicating days with
cold symptoms. At least 5 days with no cold symptoms were required before a subsequent
new cold was identified
Time points measured: contemporaneous data collection at the end of 60 days.
Primary outcome result: there were no significant differences between pranlukast and
control group in total asthma score at 8 weeks (5.5 vs 7.8, P = 0.35), and in the days in
which a child experienced a worsening of asthma symptoms (1.5 vs 1.8, P = 0.67) (data
obtained through correspondence with the author)
Secondary outcome results: higher number of colds in the control group compared to
the pranlukast group (P = 0.06), and children taking pranlukast experienced fewer days
with fever compared to the control group (P = 0.04)
Adverse events: no children discontinued study medication due to adverse events
Notes Funding: not stated.
Subgroups: Boys vs girls. 1 to 5 years vs 6 to 14 years. Boys aged 1 to 5 years had the
lower total asthma score at 8 weeks (P = 0.002), and experienced fewer cold episodes (P =
0.007). In boys, pranlukast significantly reduced total asthma score among 1- to 5-year-
olds (P = 0.010), but did not reduce it among 6- to 14-year-olds. In girls, pranlukast did
not affect total asthma score among 1- to 5-year-olds, but increased total asthma score
among 6- to 14-year-olds (P = 0.027). 60 cold episodes were reported in the pranlukast
group and 107 cases in the control group. A significant reduction in the number of cold
episodes was observed in 1- to 5-year-old boys who were treated with pranlukast (P < 0.
001)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment to either the pran-
lukast intervention group or the control
group. Randomisation conducted accord-
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ing to sex and within the predefined age
groups (1 to 5 years and 6 to 14 years)
Allocation concealment (selection bias) Unclear risk No description reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study was of open-label design. The au-
thors recognised this as a limitation of the
study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptoms were reported subjectively by
study participants. Participants and study
observers were not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk High rate of exclusions from pranlukast
group after randomisation
Selective reporting (reporting bias) Low risk All prespecified outcomes reported.
Other bias Low risk No baseline differences between groups.
Comparisons of the baseline characteristics
of the study groups were conducted using
Chi² and Mann-Whitney U-tests
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Methods Study design:3-arm, randomised, double-blind, double placebo-controlled,multicentre
clinical trial
Aim: to compare (1) omalizumab with placebo and (2) omalizumab with an ICS boost
with regard to autumn exacerbation rates when initiated 4 to 6 weeks before return to
school
Study centres and method of recruitment: 8 US urban clinical research centres, no
recruitment method information given
Dates of study: October 2011 to November 2013.
Run-in period: 2- to 12-week screening.
Duration of participation: from 4 to 6 weeks before school return until 90 days after
school return
Consent: approved by all 8 institutional review boards. Consent from guardians and
assent according to local guidelines
Power: enrolment of 453 participants (223 in the omalizumab arm, 155 in the inhaled
corticosteroid boost arm, and 75 in the placebo arm (52 in steps 2 to 4 and 23 in step 5)
) estimated to provide greater than 90% power to compare the omalizumab and placebo
arms (11.8% vs 35.9% estimated effect) and 80% power to compare the omalizumab
and ICS boost arms (12.9% vs 25.8% estimated effect)
Imputation of missing data, i.e. assumptions made for ITT analysis: main analysis
was based on modified ITT (children who were randomised, began study treatment, and
had 1 or more study contact during the 90-day outcome period were included in mITT)
. Supplemental volume included sensitivity analyses of mITT, PP, complete-case, best-
case, worst-case, and multiple imputation models
Participants Age (mean, range): 10.2 years, 6 to 17 years.
Gender: 63.4% male.
Asthma severity:National Heart, Lung and Blood Institute Expert Panel Report-3 based
steps 2-5 (mild-severe)
Diagnostic criteria: asthma diagnosis or symptoms for more than 1 year.
Number recruited: 727
Number randomised steps 2-4 (omalizumab, placebo, steroid boost): 133, 47, 138
Number randomised treatment step 5 (omalizumab, placebo): 145, 50
Number completed treatment: 439 total.
Efficacy
Number analysed steps 2-4 (omalizumab, placebo, steroid boost): 121, 43, 130
Number analysed treatment step 5 (omalizumab, placebo): 138, 46
Safety
Number analysed steps 2-4 (steroid boost, placebo): 131, 45
Number analysed treatment steps 2-5 (omalizumab, placebo): 268, 93
Withdrawals: 585 excluded pre-enrolment, 214 excluded pre-randomisation, 59 with-
drew consent and were excluded pre-enrolment, 35 withdrew consent and were excluded
pre-randomisation
• Steps 2-4: 12 excluded from omalizumab group: 5 lost to follow-up, 4 missed
injection, 2 anaphylaxis, 1 exclusionary condition. 4 excluded from placebo group: 3
lost to follow-up, 1 scheduling issue. 8 excluded from ICS boost group: 3 withdrew
consent, 2 lost to follow-up, 1 anaphylaxis, 1 missed injection, 1 scheduling issue.
• Step 5: 7 excluded from omalizumab group: 7 lost to follow-up. 4 excluded from
placebo group: 1 anaphylaxis, 1 lost to follow-up, 1 missed injection, 1 withdrew
consent.
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Inclusion criteria:
• age 6 to 17 years
• asthma diagnosis or symptoms for more than 1 year
• 1 or more asthma exacerbations (requiring systemic corticosteroids) or
hospitalisation within the prior 19 months
• positive skin test response to 1 or more perennial allergens
• body weight and total serum IgE levels suitable for omalizumab
• school attendance beginning the following August or September
• residence in a low-income census tract in predefined inner-city areas and
insurance covering standard medications
(Note: children requiring 500 µg of fluticasone or equivalent twice daily for control
during the run-in phase (step 5) were not entered into the ICS boost arm and instead
were randomised at a ratio of 3:1 to omalizumab or injected placebo.)
Exclusion criteria: not reported distinct from inclusion criteria.
Interventions Intervention: omalizumab standard dosing based on IgE and weight 4 to 6 weeks before,
until 90 days after school start
Comparison: 1) placebo, or 2) ICS boost (doubled dose).
Concomitant medication: ongoing guidelines-based management EPR-3.
Excluded medication: none reported.
Outcomes Primary outcome: asthma exacerbation in the 90-day period beginning on the first day
of each child’s school year, defined as worsening of asthma control requiring systemic
corticosteroids or hospitalisation
Secondary outcome: 11 prespecified, non-mechanistic secondary outcomes (analysed
exacerbation during 90-day intervention according to subgroups based upon: exacerba-
tion during run-in, eosinophil count, total IgE, roach IgE, age, fraction FeNO, FEV1,
BMI, ethnicity, and gender). IFNα responses to rhinovirus were measured in PBMCs
from a subset of participants
Time points measured: 2 to 4 weekly during intervention.
Primary outcome result: asthma exacerbation in the 90-day period beginning on the
first day of each child’s school year:
• omalizumab vs placebo arm: 11.3% vs 21.0%; OR 0.48, 95% CI 0.25 to 0.92
• omalizumab vs ICS boost arm: 8.4% vs 11.1%; OR 0.73, 95% CI 0.33 to 1.64
Secondary outcome results: exacerbation during 90-day intervention according to sub-
groups. The following results differed significantly according to group:
in those with an exacerbation during run-in omalizumab vs placebo OR 0.12, 95% CI
0.02 to 0.64 (steps 2-5), omalizumab vs ICS boost OR 0.05, 95% CI 0.002 to 0.98
(step 2-4);
in those with BMI centile≥ 85 omalizumab vs ICS boostOR 0.13, 95%CI 0.03 to 0.61,
(steps 2-4); in those with BMI percentile < 85 ICS boost vs placebo OR 0.19, 95% CI 0.
04 to 0.84 (steps 2-4); in those with IgE < 255 kU/L omalizumab vs ICS boost OR 0.24,
95% CI 0.06 to 0.93 (steps 2-4); in those with IgE 255 kU/L ICS boost vs placebo OR
0.24, 95% CI 0.06 to 0.87 (steps 2-4); IFN-α responses to rhinovirus were significantly
increased in the omalizumab-treated group (P = 0.03); among the omalizumab-treated
group, children with increases in ex vivo IFN-α responses to rhinovirus to greater than
the median value had a significantly lower rate of exacerbations during the outcome
period OR 0.14, 95% CI 0.01 to 0.88
Adverse events: adverse events were reported by 54.5% of children in the omalizumab
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arm and 54.8% of children in the placebo arm (P > 0.99, steps 2-5) during the interven-
tion phase. 1 or more adverse events were reported by 43.5% of children in the ICS boost
arm and 53.3% of children in the placebo arm (P = 0.30, steps 2-4). 3 cases of grade
1 anaphylaxis occurred in the ICS boost, 2 in the placebo, and 3 in the omalizumab
arm. Two serious AEs occurred during the intervention period, 1 each in the placebo
(seventh nerve palsy) and ICS boost (anaphylaxis) arm. There were no deaths and no
non-asthma-related hospitalisations during the intervention phase
Notes Funding:National institute for Allergy and Immune Diseases and an unrestricted grant
from Novartis. Omalizumab and matching placebo were donated by Novartis. The ICS
boost and matching placebo were donated by GlaxoSmithKline. Both companies had
the opportunity to comment on the study design, but they had no role in the trial’s
performance, data analysis,manuscript preparation, or decision to submit themanuscript
for publication. Adrenaline auto injectors were provided by Mylan
Subgroups: 11 subgroups were based on: exacerbation during run-in, eosinophil count,
total IgE, roach IgE, age, FeNO, FEV1, BMI, ethnicity, and gender. A prespecified
subgroup analysis was conducted considering children with an exacerbation during the
run-in phase. Omalizumab was more efficacious than both placebo (6.4% vs 36.3%;
OR 0.12, 95% CI 0.02 to 0.64) and ICS boost (2.0% vs 27.8%; OR 0.05, 95% CI 0.
002 to 0.98)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised, computer-based random allo-
cation scheme
Allocation concealment (selection bias) Low risk Described as centralised. No information
on allocation concealment in report, but
study authors confirmed that allocation
was concealed using a third party and iden-
tical containers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo, inhalers and injections. No evi-
dence that adverse events differed between
placebo and interventions, and no other
reasons to suspect participants could iden-
tify to which group they had been assigned.
Participants and other staff blinded. Un-
blinded nurses administered injections but
not involved in outcome measurement
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mix of objective and subjective outcomes,
but assessors all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analysis was modified intention-
to-treat restricted to childrenwhowere ran-
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domised, began study treatment, and had
more than or equal to 1 study contact dur-
ing the 90-day outcome period. There was
good retention (94%) and similar dropout
rates and reasons between groups
Selective reporting (reporting bias) Low risk Secondary outcomes predefined. All re-
ported in online supplement
Other bias Low risk Groups balanced according to baseline
characteristics.
Weiss 2010
Methods Study design: randomised, double-blind, placebo-controlled, multicentre study
Aim: to determine the effectiveness of montelukast therapy in reducing asthma burden
in children when initiated prophylactically on school return
Study centres and method of recruitment: 165 allergy and clinical paediatric practices
in the United States and Canada. Hospital-led recruitment. No recruitment information
given
Dates of study: 28 June 2006 to 20 November 2006.
Run-in period: 2- to 12-week screening.
Duration of participation: 10 weeks.
Consent: approved by local institutional review boards or ethical review committees
with informed consent obtained from participants and parents or guardians
Power: assuming a treatment difference of 5% and a standard deviation of 24%, 495
evaluable participants in each treatment group was estimated to provide 90% power (2-
sided alpha 0.05) to demonstrate the superiority of montelukast
Imputation of missing data, i.e. assumptions made for ITT analysis: efficacy analysis
was based on the analysis set population, which included all children who had received
at least 1 dose of study medication and had a valid measurement of the percentage of
days with worsening asthma during the study period (derived from at least 7 days of
diary data). All randomised children who had received at least 1 dose of study drug were
included in the safety analysis
Participants Age (mean, range): 9.9 years, 6 to 14 years.
Gender: 61.2% male montelukast group, 59.5% male placebo group.
Asthma severity: 30% prescribed inhaled corticosteroids at randomisation (likely low/
moderate)
Diagnostic criteria: history of chronic asthma.
Number recruited: 1162
Number randomised (intervention, control): 580, 582
Number completed (intervention, control): 536, 545
Number analysed (intervention, control): efficacy analysis 499, 499; safety analysis
566, 566.
Withdrawals:
• 44 montelukast group: 5 clinical adverse events, 4 protocol deviation, 1
laboratory adverse event, 1 lack of efficacy, 12 lost to follow-up, 1 moved, 15 withdrew
consent, 5 other
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• 37 control group: 5 clinical adverse events, 4 protocol deviation, 5 lack of efficacy,
7 lost to follow-up, 2 moved, 7 withdrew consent, 7 other
Inclusion criteria:
• age 6 to 14 years
• history of chronic asthma for at least 1 year, in association with the need for
treatment and asthma medication 6 months preceding screening
• history of at least 1 asthma exacerbation in the previous year, in conjunction with
a cold
• alteration in environment differing from their typical school or education
environment throughout August/September
Exclusion criteria:
• FEV1 < 60%
• corticosteroid use other than ICS within 4 weeks of randomisation
• LABA or LTRA use within 10 days of randomisation
• hospitalisation within 4 weeks or more than 3 times in the previous year
• moving to a different area for greater than 7 days after school start
Interventions Intervention:montelukast 5 mg from the night before the first day of school for 8 weeks
Comparison: matching placebo
Concomitant medication: usual medications
Excluded medication: none reported beyond exclusion criteria
Outcomes Primary outcome: percentage of days with worsening asthma symptoms, defined as 1
or more of: increased beta-agonist use > 70% from baseline and a minimum increase of 2
puffs; increased daytime symptoms score >50%frombaseline; awake ’all night’; increased
ICS use ≥ 100% from baseline or OCS rescue for worsening asthma; unanticipated
visits to a doctor, emergency department, or hospital for asthma
Secondary outcomes:
• individual components of the primary composite endpoint
• occurrence of any adverse event
• any serious adverse event
• any drug-related adverse event
• discontinuation due to adverse events
Time points measured: 4, 8, and 10 weeks.
Primary outcome result: percentage of days with worsening asthma symptoms: mon-
telukast 24.3% vs placebo 27.2%; least squares means difference 3.0, 95% CI 6.21 to
0.29; P = 0.07 (OR for use of OCS obtained from authors and unpublished: OR 0.79,
95% CI 0.59 to 1.06)
Secondary outcome results: no significant changes in components of primary outcome,
safety outcomes, or interaction terms for subgroup analyses
Adverse events: 4 SAEs in the intervention group, 1 SAE in the placebo group. No SAE
thought to be treatment related. The most common AEs were upper respiratory tract
infections
Notes Funding: Merck & Co.
Subgroups: intervention better than control in boys and children 10 to 14 years, but
interaction terms for age and gender non-significant. No difference between groups
according to inhaled corticosteroid use at entry, presence of cold symptoms, or according
to individual components of the primary outcome
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• age group: percentage days worsening symptoms intervention vs control 10 to 14
years: 21.4% vs 26.4%; 6 to 9 years: 27.4% vs 27.7%
• gender: percentage days worsening symptoms intervention vs control boys: 23.7%
vs 28.9%; girls: 25.3% vs 25.0%
Additional post hoc subgroup analyses suggested an increased percentage of days with
asthma symptoms in the placebo compared to the intervention group at 3 to 4 weeks
after school return and near-significant superiority of intervention if school return is later
than 15 August
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, randomisation
schedule generated by study statistician
Allocation concealment (selection bias) Unclear risk No description of schedule. Numbered
containers, not specified whether identical
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical placebo used. Study double-
blinded including laboratory technicians,
monitors, and study site personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded, outcome systematic but
largely subjective participant-reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analysis based on a modified in-
tention-to-treat design, including all chil-
dren who had received at least 1 dose of
study medication and had a valid measure-
ment of the percentage of days with wors-
ening asthma during the study period (de-
rived from at least 7 days of diary data).
There was no imputation of missing data,
but similar dropout rates and reasons be-
tween groups
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Generally balanced groups at baseline ex-
cept inhaled corticosteroids last year inter-
vention 54.1% vs placebo 48.7%
AE: adverse event
BMI: body mass index
CI: confidence interval
CPRD: Clinical Practice Research Datalink
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EPR-3: Expert Panel Report 3
GP: general practitioner
ICS: inhaled corticosteroids
IgE: immunoglobulin E
IFNα: interferon alpha
ITT: intention-to-treat
FeNO: fractional exhaled nitric oxide
FEV1: forced expiratory volume in the first second of expiration
LABA: long-acting beta-agonist
LTRA: leukotriene receptor antagonist
mITT: modified intention-to-treat
NHS: National Health Service
OCS: oral corticosteroid
OR: odds ratio
PBMCs: peripheral blood mononuclear cells
PP: per protocol
SAE: serious adverse event
QALY: quality-adjusted life year
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anah 1980 Not restricted to children (≤ 18 years). The average age of participants was 27.1 years. Also did not specifically
address problems associated with school return
Bruce 1977 Not restricted to children (≤ 18 years). Sample group selected from adult volunteers. Also relates to the ragweed
season rather than specifically addressing school return
Bueving 2004 Incorrect seasonal focus. Children participated during influenza season. Study lacks specific purpose of reducing
school-return exacerbations of asthma
Busse 2011 Incorrect methodology. Exacerbations after school return were reported as an outcome, but this was a post hoc
analysis. The study was not a randomised controlled trial of an intervention specifically designed to reduce
exacerbations after school return
Coffman 1971 Does not refer to asthma and incorrect seasonal focus. Study refers to hay fever grass pollen allergy during the
summer months between May and July
Corren 1992 Study not restricted to children (≤ 18 years). Mean age for placebo group was 35.1 years. Mean age for nasal
beclomethasone dipropionate group was 36.1 years. Also study was designed to reduce asthma and rhinitis
symptoms during the autumn pollen season rather than addressing the problem of school return
Crane 1998 No mention of seasonal exacerbations of asthma
Engstrom 1970 Incorrect seasonal focus. Main seasons of symptomatology extended from May to August
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Esquivel 2016 No mention of seasonal exacerbations of asthma. This study examined data from the Preventative Omalizumab
or Step-up Therapy for Severe Fall Exacerbations (PROSE) study reported in Teach 2015a but considered ’colds’
as the outcome.
Fang 2001 Not limited to children (≤ 18 years). Mean age was 37 years. Also intervention not specifically designed to reduce
exacerbations after school return
Ford 1969a Not restricted to children (≤ 18years). All but one participant older than30 years. Also interventionnot specifically
designed to reduce exacerbations after school return
Ford 1969b Incorrect seasonal focus, referred to pollinotic asthma in the height of spring
Gerald 2012 Incorrect methodology. Purpose was not to compare intervention designed to reduce school-return exacerbations
of asthma with usual care. Randomised controlled cross-over trial of year-round hand sanitiser compared to
normal hand hygiene
Grant 1995 Not restricted to children (≤ 18 years). Aged 12 to 70 years. Also intervention not specifically designed to reduce
exacerbations after school return but rather to prevent exacerbations associated with the pollen season
Halterman 2002 No mention of seasonal exacerbations of asthma
Halterman 2004 No mention of seasonal exacerbations of asthma
Halterman 2005 No mention of seasonal exacerbations of asthma
Joseph 2005 No mention of seasonal exacerbations of asthma
Levy 2006 No mention of seasonal exacerbations of asthma
Lewis 2012 No mention of seasonal exacerbations of asthma
Prazma 2015 Purpose was not to compare intervention designed to reduce school-return exacerbations of asthma with usual
care. Compared fluticasone propionate/salmeterol to fluticasone propionate rather than a usual care control
Yoshihara 2014 Purpose was not to compare intervention designed to reduce school-return exacerbations of asthma with usual
care. Compared suplatast tosilate to mequitazine rather than to a usual care control
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D A T A A N D A N A L Y S E S
Comparison 1. Interventions for autumn exacerbations of asthma versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbations defined according
to the review’s primary
outcome
1 Odds Ratio (Random, 95% CI) Subtotals only
1.1 Omalizumab
interventions
1 348 Odds Ratio (Random, 95% CI) 0.48 [0.25, 0.92]
1.2 Omalizumab intervention
(stage 5 asthma)
1 184 Odds Ratio (Random, 95% CI) 0.37 [0.17, 0.81]
1.3 Steroid boost intervention
(stage 2-4 asthma)
1 173 Odds Ratio (Random, 95% CI) 0.86 [0.32, 2.31]
2 Exacerbations defined according
to study-specific definitions
4 Odds Ratio (Random, 95% CI) Subtotals only
2.1 Montelukast interventions 2 1192 Odds Ratio (Random, 95% CI) 0.50 [0.17, 1.46]
2.2 Pranlukast intervention 1 121 Odds Ratio (Random, 95% CI) 0.67 [0.16, 2.80]
2.3 Behavioural intervention 1 9118 Odds Ratio (Random, 95% CI) 1.13 [0.96, 1.34]
3 Adverse effects 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Omalizumab intervention
(stage 2-5 asthma)
1 361 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.61, 1.58]
3.2 Steroid boost intervention
(stage 2-4 asthma)
1 176 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.33]
3.3 LTRA interventions 2 1326 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.63, 1.32]
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KCP drafted the protocol.
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KCP, DK, and MA selected studies for inclusion in the review.
KCP, KMH, DK, and MA reviewed the protocol and the review for accuracy before submission.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Our original intention was to include randomised controlled trials, quasi-randomised controlled trials, and observational studies. We
believed observational trials presenting exacerbation data on a month-by-month basis might identify treatments or other potentially
modifiable factors associated with a lessening of the autumn peak in asthma exacerbations. After conducting searches, we did not feel
we could reliably identify all studies presenting these data since it was difficult to identify search terms to capture studies where seasonal
differences were not the main focus. This review was therefore restricted to randomised controlled trials of interventions specifically
designed to reduce asthma exacerbations in children after the return to school for the autumn term. The comparator was usual care
since there are no established interventions for this problem. In a pragmatic change to our protocol due to the small number of studies
returned, we decided not to restrict the review to school-age children, since the autumn peak is less pronounced but still observed in
preschool-aged children, but does not occur appreciably in adults.
Unfortunately, due to the small number of studies identified and to differences in both interventions and outcomes, it was not possible
to conduct subgroup or sensitivity analyses. We were also unable to assess any secondary outcomes except adverse events due to lack of
data relating to these outcomes in the included trials. When pooling data from studies using a comparable intervention, we employed
a Mantel-Haenszel random-effects model for the meta-analysis of adverse effects, since these data were reported as absolute values in
the included studies. We used an inverse variance model for the exacerbation outcome; however, as although odds ratios were reported
or obtainable from study authors, the absolute number of children was not appropriate for use in Teach 2015a and Weiss 2010 studies,
where the authors had adjusted for covariables in the odds ratio calculation.
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